PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Prog Neurobiol. Author manuscript; available in PMC 2011 October 1.
Published in final edited form as:
PMCID: PMC2939268
NIHMSID: NIHMS211607

The nicotinic acetylcholine receptor CHRNA5/A3/B4 gene cluster: Dual role in nicotine addiction and lung cancer

Abstract

More than 1 billion people around the world smoke, with 10 million cigarettes sold every minute. Cigarettes contain thousands of harmful chemicals including the psychoactive compound, nicotine. Nicotine addiction is initiated by the binding of nicotine to nicotinic acetylcholine receptors, ligand-gated cation channels activated by the endogenous neurotransmitter, acetylcholine. These receptors serve as prototypes for all ligand-gated ion channels and have been extensively studied in an attempt to elucidate their role in nicotine addiction. Many of these studies have focused on heteromeric nicotinic acetylcholine receptors containing α4 and β2 subunits and homomeric nicotinic acetylcholine receptors containing the α7 subunit, two of the most abundant subtypes expressed in the brain. Recently however, a series of linkage analyses, candidate-gene analyses and genome-wide association studies have brought attention to three other members of the nicotinic acetylcholine receptor family: the α5, α3 and β4 subunits. The genes encoding these subunits lie in a genomic cluster that contains variants associated with increased risk for several diseases including nicotine dependence and lung cancer. The underlying mechanisms for these associations have not yet been elucidated but decades of research on the nicotinic receptor gene family as well as emerging data provide insight on how these receptors may function in pathological states. Here, we review this body of work, focusing on the clustered nicotinic acetylcholine receptor genes and evaluating their role in nicotine addiction and lung cancer.

Keywords: Nicotinic acetylcholine receptors, CHRNA5/A3/B4 gene cluster, Nicotine addiction, Lung cancer, Genome-wide association studies

1. Introduction

The molecular cloning of nicotinic acetylcholine receptors (nAChRs) from brain cDNA libraries in the mid-1980s was a watershed event as it opened the window to not only a molecular understanding of cholinergic signaling within the nervous system, but also to a structural understanding of how members of the Cys-loop superfamily of ligand-gated ion channels function. In addition to neuronal and muscle nAChRs, members of this family include the ionotropic receptors for glycine, 5-hydroxytryptamine (5-HT3), and γ-aminobutyric acid (GABAA and GABAC) (Dani and Bertrand, 2007; Le Novère and Changeux, 1995). As the cloning frenzy subsided, a tremendous amount of effort was put forth to understand the pharmacological and biophysical diversity of nAChRs. As a result, nAChRs are among the most well understood allosteric membrane proteins from a structural and functional point of view (Albuquerque et al., 2009). Furthermore, nAChRs have emerged as key therapeutic targets for a variety of pathologies including schizophrenia, depression, attention deficit hyperactivity disorder, Alzheimer’s disease and of course, tobacco addiction (Arneric et al., 2007; Levin and Rezvani, 2007; Romanelli et al., 2007; Taly et al., 2009). More recently, genetic studies have identified single nucleotide polymorphisms (SNPs) in the chromosomal locus encoding three nAChR genes as risk factors for 1) nicotine dependence 2) lung cancer, 3) chronic obstructive pulmonary disease, 4) alcoholism and 5) peripheral arterial disease (Amos et al., 2008; Berrettini et al., 2008; Bierut et al., 2008; Caporaso et al., 2009; Freathy et al., 2009; Hung et al., 2008; Pillai et al., 2009; Saccone et al., 2009b; Saccone et al., 2007; Sasaki et al., 2009; Schlaepfer et al., 2008; Stevens et al., 2008; Thorgeirsson et al., 2008; Weiss et al., 2008). This cluster of nAChR genes encodes the α3, α5 and β4 subunits (designated CHRNA5/A3/B4) (Boulter et al., 1990). As a result of these genetic studies, new attention has been brought to bear on the CHRNA5/A3/B4 genes and their encoded subunits. This review summarizes recent work on the clustered nAChR subunits highlighting their structure, function, and expression in a variety of pathological conditions.

2. Neuronal nicotinic acetylcholine receptors

2.1 General overview

Signaling through neuronal nAChRs underlies several fundamental biological processes both during development and in the adult (Albuquerque et al., 2009). In the central nervous system (CNS), presynaptic nAChRs modulate release of most classical neurotransmitters including norepinephrine, acetylcholine (ACh), glutamate and GABA (McGehee et al., 1995). Postsynaptic nAChRs are intimately involved in fast ACh-mediated synaptic transmission in addition to activity-dependent gene expression, which is critical for synaptic plasticity (Albuquerque et al., 2009; Dani and Bertrand, 2007; Hu et al., 2002; Ji et al., 2001). Within the peripheral nervous system (PNS), nAChRs mediate fast excitatory transmission in most, if not all, autonomic ganglia and are involved in modulating visceral and somatic sensory transmission (Boyd et al., 1991; Genzen et al., 2001; Hu and Li, 1997; Steen and Reeh, 1993; Sucher et al., 1990; Wang et al., 2002b). More recently, numerous studies have revealed the expression of nAChRs on non-neuronal cells such as lung, glia, keratinocytes, endothelial cells, as well as cells of the digestive and immune systems, and evidence is accumulating indicating that the receptors play crucial roles in signal transduction underlying many physiological processes outside the nervous system (Arredondo et al., 2001; Battaglioli et al., 1998; Gahring et al., 2004b; Gahring and Rogers, 2006; Kawashima and Fujii, 2003; Macklin et al., 1998; Maus et al., 1998; Nguyen et al., 2000; Spindel, 2003; Wang et al., 2001; Wessler and Kirkpatrick, 2008). The importance of nAChR-mediated signaling is reflected in the many pathologies in which cholinergic signal transduction is compromised. For example, significant alterations in nAChR expression and function have been documented in several diseases such as Alzheimer’s disease, autosomal dominant nocturnal frontal lobe epilepsy, megacystis-microcolon-intestinal hypoperistalsis syndrome, Parkinson’s disease, schizophrenia, and Tourette’s disease (De Fusco et al., 2000; Isacson et al., 2002; Lena and Changeux, 1997; Perl et al., 2003; Perry et al., 2001; Quik, 2004; Quik et al., 2007; Richardson et al., 2001; Silver et al., 2001; Steinlein et al., 1995; Teaktong et al., 2003; Whitehouse et al., 1988; Zanardi et al., 2002). In addition, nAChRs are key players in the initial steps and subsequent downstream health consequences of nicotine addiction (Kedmi et al., 2004; Laviolette and van der Kooy, 2004). Coupled to this is a growing awareness that nAChRs may directly contribute to the pathogenesis of lung cancer (Catassi et al., 2008; Egleton et al., 2008; Schuller, 2008, 2009; Song et al., 2008).

2.2. Structural and functional properties of nAChRs

Neuronal nAChRs are transmembrane proteins that form pentameric structures assembled from a family of subunits that include α2-α10 and β2-β4 (Brejc et al., 2001; Cooper et al., 1991). Each nAChR subunit consists of an approximately 200-residue extracellular N-terminus, four transmembrane segments (designated M1–M4), a variable intracellular loop (100–200 residues) between M3 and M4, and an extracellular C-terminus (4–28-residue, Fig. 1A) (Corringer et al., 2000). The N-terminus contains the ACh-binding domain (Eisele et al., 1993) with the interface between adjacent subunits forming a hydrophobic pocket that serves as the agonist-binding site. The M2 transmembrane segment of all 5 subunits forms the conducting pore of the channel, with regions in the M1–M2 intracellular loop contributing to cation permeability and agonist binding affinities (Corringer et al., 2000; McGehee and Role, 1995). When activated by an agonist in native or heterologous expression systems, nAChRs exhibit a rapid (500 ms to peak current, [ACh] = EC50) inward current that desensitizes (Barnard et al., 1982) and is potentiated by calcium ions (Vernino et al., 1992). The functional diversity exhibited by the neuronal nAChR family is a consequence, in large part, of the differential expression of the various subunit genes leading to the incorporation of distinct subunits into mature receptors.

Fig. 1
nAChR Structure

Much of what is known about the biophysical and pharmacological properties of nAChRs is based on studies in heterologous expression systems (McGehee and Role, 1995). These systems make use of nAChR mRNA or cRNA injected into Xenopus oocytes as well as nAChR cDNA transfected into mammalian cell lines in order to express nAChR subunits singly or in combination. The propensity for nAChR subunits to form homomeric subtypes was determined by expressing subunits singly. When expressed alone, α7, α8, α9, and α10 are able to form functional receptors (Couturier et al., 1990a; Gerzanich et al., 1994). In contrast, other α subunits require the presence of β subunits to form functional receptors (Fig. 1B).

Of the clustered receptor subunit genes, co-expression of α3 and β4 nicotinic receptor subunit cRNA results in functional receptors with a single channel conductance, γ, of ~24 pS (McGehee and Role, 1995; Nelson and Lindstrom, 1999). ACh and nicotine are less potent agonists of α3β4 nAChRs compared to the prototypic high affinity α4β2 nAChRs (Table 2). In addition, α3 can coassemble with β2 nAChR subunits and form a functional receptor (Table 2) (Boulter et al., 1987; Wada et al., 1988). Unlike α3, the α5 subunit fails to form functional receptors when co-expressed with either β4 or β2 subunits (Boulter et al., 1987; Couturier et al., 1990b). Although the α5 subunit harbors the characteristic viscinal cysteines in the large extracellular domain, a tyrosine residue (Tyr198) required for ligand binding has been substituted with an aspartic acid residue, likely explaining the lack of functionality of this subunit when expressed with either β subunit alone (Albuquerque et al., 2009; Karlin, 2002). Thus, for several years after its initial cloning, the impact of the α5 subunit on nAChR function was poorly understood. This mystery was solved when α5 was co-expressed with both α4 and β2 subunits (Ramirez-Latorre et al., 1996). ACh-evoked currents from Xenopus oocytes expressing the three subunits were distinct from ACh-evoked currents in oocytes expressing only α4 and β2 subunits. In particular, expression of α5 dramatically shifted the ACh concentration response curve to the right and significantly increased the predominant single channel conductance (α4β2 = 24 pS, α4α5β2 = 44 pS at −100 mV). Finally, cysteine mutagenesis of amino acid residues in the M2 domain of the α5 nAChR subunit conferred MTSET sensitivity to α4β2* nAChRs indicating participation of the α5 subunit M2 domain with the pore of assembled receptors (“*” denotes containing, (Lukas et al., 1999). Later studies analyzed the impact of α5 expression on α3β2 and α3β4 nAChR function. In contrast to its effects on the pharmacology of α4β2 nAChRs, α5 expression increased the sensitivity of α3β2 nAChRs to nicotine and ACh (Table 2)(Wang et al., 1996). Surprisingly, the ACh/nicotine concentration-response relationship between α3β4 and α3α5β4 nAChRs was found to not dramatically differ (Wang et al., 1996). However, α5 subunit expression did accelerate the rate of desensitization of these receptors. In addition, expression of the α5 subunit reduced channel sensitivity to agonist in α3β4 nAChRs with engineered point mutations in the M2 domain that renders receptors hypersensitive to agonist definitively illustrating that α5 nAChR subunits can co-assemble with α3β4 nAChRs (Groot-Kormelink et al., 2001). Finally, coassembly of the α5 subunit with α3β2 or α3β4 nAChRs increases the calcium permeability of the resulting receptors (Gerzanich et al., 1998) indicating that these receptors could play significant roles in the initiation of ACh-induced signaling cascades under normal and pathological condition. In addition to uncovering a functional role of the α5 nAChR subunit, these studies demonstrated that a portion of functional nAChRs in native tissue likely consist of heteropentamers containing three or more distinct subunits.

Table 2
ACh and Nicotine Potency for Various nAChR Subtypes

2.3 The CHRNA5/A3/B4 gene cluster

The CHRNA5/A3/B4 nAChR subunit genes are found in a tight cluster in chromosomal region 15q24–25 (Fig. 1C) (Boulter et al., 1990). Admixtures of the nAChR subunits encoded by this locus form the predominant nicotinic receptor subtypes expressed in the PNS (Conroy and Berg, 1995; Covernton et al., 1994; Flores et al., 1996; Rust et al., 1994; Vernallis et al., 1993) as well as at key sites in the CNS such as the medial-habenula (Gotti et al., 2007; Grady et al., 2009). To determine the function of the clustered nAChR subunits, knockout (KO) mice have been generated. Mice that do not express the α3 subunit usually die within a week of birth due to multi-organ dysfunction (Xu et al., 1999a). α3 KO mice develop enlarged bladders causing bladder infection, dribbling urination, and urinary stones – a phenotype resembling that of a rare human condition called megacystis-microcolon-intestinal hypoperistalsis syndrome (Xu et al., 1999a). Consistently, patients with this disease do not appear to express α3 mRNA (Richardson et al., 2001). α3 KO mice also display extreme pupil dilation and lack of pupil contraction in response to light and have retinal wave activity with altered spatiotemporal properties delaying the refinement of retinal ganglion cell dendrites (Bansal et al., 2000; Xu et al., 1999a). Bladder contraction in response to nicotine is also lost. In addition, electrophysiological characterization shows that nicotine-induced whole-cell currents are abolished in the superior cervical ganglion (SCG) of α3 KO mice.

In contrast to the α3 KO mice, α5 and β4 KO mice are both viable and lack any gross abnormalities (Wang et al., 2003; Wang et al., 2002a; Xu et al., 1999a). α5 KO mice do exhibit abnormal cardiac parasympathetic ganglionic transmission and are less sensitive to acute nicotine treatment. Loss of α5 selectively affects axonal nAChRs in the SCG while leaving somatodendritic receptors unaffected (Fischer et al., 2005). Similarly, ganglionic transmission is impaired in β4 KO mice, attenuating ileal and bladder contractile responses to nicotinic agonists. Nicotine-induced whole cell currents in the SCG of β4 KO mice are also reduced but still present, suggesting that compensation from another subunit (i.e. β2) may be occurring (Xu et al., 1999b). Consistent with this notion, nicotine-induced currents in the SCG are abolished in double β2-β4 KO mice. Moreover, double β2-β4 KO mice exhibit similar bladder and pupil dysfunction as α3 KO mice. Taken together, these studies indicate that the clustered nAChR subunits are essential for normal ganglionic function and that compensation by β2 can occur with the loss of β4.

In addition to their PNS-specific phenotypes, α3, α5 and β4 KO mice also exhibit CNS-centric abnormalities compared to WT mice. For example, α3, α5 and β4 KO animals are resistant to nicotine-induced seizures compared to their respective WT littermates and are not as sensitive to nicotine-induced inhibition of locomotion (Salas et al., 2004a; Salas et al., 2003a). β4 KO mice also appear less anxious compared to WT mice in two specific anxiety assays suggesting a role for β4* nAChRs in modulating anxiogenic stimuli (Salas et al., 2003b). These mice also have a lower core body temperature which is less responsive to modulation by acute nicotine infusion (Sack et al., 2005).

3. Regulation of CHRNA5/A3/B4 expression

3.1 Expression patterns of the CHRNA5/A3/B4 genes

Although the initial focus of nAChR expression was in the nervous system, it is now clear that “neuronal” nAChR genes are also expressed in non-neuronal cells where they participate in a number of fundamental processes (Gahring and Rogers, 2006; Sharma and Vijayaraghavan, 2002; Spindel, 2003; Wessler and Kirkpatrick, 2008). This is certainly true for the CHRNA5/A3/B4 subunit genes. The CHRNA5/A3/B4 genes are co-expressed in many cell types, thus their clustering may reflect coordinate regulation (Table 1). This hypothesis is supported by the fact that the transcriptional activities of the promoter regions of the three genes are regulated by many of the same transcription factors (Fig. 2). However, the CHRNA5/A3/B4 genes are not always co-expressed, suggesting that independent regulation of each gene also occurs (Table 1 and Fig. 2.).

Fig. 2
Transcriptional regulation of the CHRNA5/A3/B4 gene cluster. (A) Protein-DNA interactions regulate expression of the clustered nAChR subunit genes. Coding regions of the subunits are represented as light green boxes with arrows indicating the direction ...
Table 1
Expression of the CHRNA5/A3/B4 Genes

3.1.1 CHRNA3

In the nervous system, the α3 subunit is highly expressed in the periphery with a more restricted expression profile in the CNS (Gotti and Clementi, 2004; Greenbaum and Lerer, 2009). In the PNS, α3 subunit expression is seen in trigeminal sensory neurons (Flores et al., 1996; Liu et al., 1998), facial motoneurons (Senba et al., 1990), retina (Feller, 2002; Moretti et al., 2004), dorsal root ganglia (Zoli et al., 1995) as well as SCG, adrenal medulla, spenopalatine and otic ganglia (Rust et al., 1994). Centrally, the α3 subunit is expressed in the brainstem (Morley, 1997), cerebellum (Hellström-Lindahl et al., 1999; Turner and Kellar, 2005), spinal cord (Hellström-Lindahl et al., 1998; Keiger et al., 2003), substantia nigra (Azam et al., 2002), medial habenula (Grady et al., 2009; Zoli et al., 1995), pineal gland (Zoli et al., 1995), hippocampus (Gahring et al., 2004a; Guan et al., 2002; Hellström-Lindahl et al., 1999; Terzano et al., 1998; Winzer-Serhan and Leslie, 1997), cortex (Guan et al., 2002; Hellström-Lindahl et al., 1999) thalamus (Perry et al., 2002; Terzano et al., 1998), ventral tegmental area (Greenbaum and Lerer, 2009; Perry et al., 2002) and interpeduncular nucleus (Grady et al., 2009; Perry et al., 2002; Winzer-Serhan and Leslie, 1997).

Outside the nervous system, the α3 subunit is expressed in human oral keratinocytes (Arredondo et al., 2005; Arredondo et al., 2001; Conti-Tronconi et al., 1994) where its expression, both mRNA and protein, is increased following exposure to nicotine (Arredondo et al., 2005; Arredondo et al., 2001; Zia et al., 2000). α3-containing nAChRs are also expressed in lymphocytes (Benhammou et al., 2000), the gastrointestinal tract (Flora et al., 2000a; Glushakov et al., 2004), vascular endothelial cells (Macklin et al., 1998; Wang et al., 2001), polymorphonuclear cells (Benhammou et al., 2000), bronchial epithelium (Maus et al., 1998; Wang et al., 2001) and O2A progenitors (Rogers et al., 2001). The α3 subunit is also expressed in lung (Improgo et al., 2010; Lam et al., 2007; Sartelet et al., 2008) and its expression increases in small cell lung carcinoma (Improgo et al., 2010).

3.1.2 CHRNA5

Similar to the α3 subunit, the α5 subunit is most highly expressed in the PNS but is also expressed in several key regions of the CNS (Gotti and Clementi, 2004; Greenbaum and Lerer, 2009). Centrally, α5 is expressed primarily in the cerebellum and thalamus (Flora et al., 2000a) but is also detected in the cortex, hippocampus, brainstem, spinal cord, habenula, interpeduncular nucleus and other midbrain nuclei (Azam et al., 2002; Gahring et al., 2004a; Grady et al., 2009; Hellström-Lindahl et al., 1998; Keiger et al., 2003; Wada et al., 1990; Zoli et al., 2002). In the PNS, α5 is expressed in most autonomic ganglia (Flora et al., 2000a; Liu et al., 1998) and the retina (Moretti et al., 2004).

In addition to the nervous system, α5 subunit expression has been detected in the gastrointestinal tract, where its expression is substantially higher than that of the α3 subunit, thymus and testis (Flora et al., 2000a; Glushakov et al., 2004). Furthermore, the α5 subunit is expressed in many of the same cell types as the α3 and β4 subunits including oral epithelium (Arredondo et al., 2005; Arredondo et al., 2001), vascular endothelial cells (Macklin et al., 1998; Wang et al., 2001), bronchial epithelium (Maus et al., 1998; Wang et al., 2001), O2A progenitors (Rogers et al., 2001) and a variety of immune cells (Wessler and Kirkpatrick, 2008).

3.1.3 CHRNB4

As with the other two genes in the nAChR cluster, the β4 subunit gene is widely expressed in the PNS with more limited expression centrally (Gotti and Clementi, 2004). β4 expression is relatively high in trigeminal sensory neurons (Flores et al., 1996; Liu et al., 1998) as well as the superior cervical, dorsal root, spenopalatine and otic ganglia and sympathetic neurons (Mandelzys et al., 1994; Rust et al., 1994; Zoli et al., 1995). The β4 subunit is also expressed in the adrenal medulla (Di Angelantonio et al., 2003) with lower expression in the retina (Moretti et al., 2004). In the CNS, β4 expression is particularly high in the olfactory bulb, pineal gland, medial habenula and interpeduncular nucleus (Dineley-Miller and Patrick, 1992; Grady et al., 2009; Winzer-Serhan and Leslie, 1997) with lower expression in other thalamic nuclei, the cortex, hippocampus, spinal cord, cerebellum and midbrain (Azam et al., 2002; Gahring et al., 2004a; Hellström-Lindahl et al., 1998; Keiger et al., 2003; Perry et al., 2002; Quik et al., 2000; Turner and Kellar, 2005).

Outside the nervous system, there is again significant overlap of β4 expression with α3 and α5 expression. β4 is expressed in multiple cell types of the intestine (Flora et al., 2000a; Glushakov et al., 2004), vascular endothelial cells (Macklin et al., 1998), oral keratinocytes (Arredondo et al., 2005; Arredondo et al., 2001), polymorphonuclear cells (Benhammou et al., 2000), bronchial epithelium (Maus et al., 1998; Wang et al., 2001) and O2A progenitors (Rogers et al., 2001). Finally, β4 is co-expressed with α3 and α5 in lung (Improgo et al., 2010; Lam et al., 2007; Sartelet et al., 2008) and is also up-regulated in lung cancer (see below) (Improgo et al., 2010).

3.2. Transcriptional regulation of the CHRNA3/A5/B4 genes

The co-expression of the CHRNA3/A5/B4 genes coupled with their genomic clustering suggests they may share common regulatory mechanisms in addition to specific regulation of each gene. Further support for this idea comes from several observations. First, nucleotide sequencing of the individual gene promoters revealed that they each lack classical CAAT and TATA boxes (Boulter et al., 1990). Instead, the promoters are GC-rich and contain several binding sites for the transcription factors, Sp1 and Sp3 (Fig. 2). Both Sp factors positively regulate transcription of each of the clustered subunit genes through multiple binding sites in each individual promoter (Bigger et al., 1996; Bigger et al., 1997; Boyd, 1996; Campos-Caro et al., 2001; Campos-Caro et al., 1999; Flora et al., 2000b; Melnikova and Gardner, 2001; Melnikova et al., 2000a; Terzano et al., 2000; Valor et al., 2002; Yang et al., 1995). Chromatin Immunoprecipitation (ChIP) experiments demonstrated Sp1 binding activity in the context of native chromatin for all three promoters (Benfante et al., 2007; Scofield et al., 2008). It is likely that Sp1 is involved in tethering the basal transcription machinery to the TATA-less nAChR subunit gene promoters (Pugh and Tjian, 1991). Second, in addition to the Sp factors, the CHRNA3/A5/B4 promoter regions can directly interact with and be trans-activated by the more spatially restricted regulatory factors Sox10 and SCIP/Tst-1/Oct-6 (Fig. 2)(Fyodorov and Deneris, 1996; Liu et al., 1999; Yang et al., 1994). Third, the mRNA levels of the CHRNA3/A5/B4 genes are coordinately up-regulated during neural development (Corriveau and Berg, 1993; Levey et al., 1995; Levey and Jacob, 1996) and coordinately down-regulated following denervation (Zhou et al., 1998). Perhaps the most compelling evidence for a coordinated regulatory scheme comes from the Deneris lab, which showed that two transcriptional regulatory elements, β43′ and conserved noncoding region 4 (CNR4), play key roles in directing expression of the clustered nAChR genes in a tissue-specific manner with β43′ being important for expression in the adrenal gland and CNR4 being critical for expression in the pineal gland and superior cervical ganglion (Fig. 2)(Xu et al., 2006). CNR4 is likely to play an important role in directing nAChR gene expression in the brain as well (Xu et al., 2006). In addition to these shared regulatory features, the CHRNA3/A5/B4 genes are subject to gene-specific regulation.

3.2.1. CHRNA3

In vitro experiments have shown that the paired-like homeodomain transcription factor, PHOX2A, regulates transcription from the α3 promoter (Benfante et al., 2007). PHOX2A does not appear to bind directly to DNA, however, as the DNA-binding domain does not need to be completely intact for PHOX2A to regulate transcription from the α3 promoter (Benfante et al., 2007). Co-immunoprecipitation experiments demonstrate a physical interaction between Sp1 and PHOX2A, suggesting that PHOX2A is tethered to the α3 promoter through its interaction with Sp1, similar to the interactions of Sp1 with homeodomain transcription factors observed in other systems (Shimakura et al., 2006).

As briefly described above, the POU domain factor SCIP/Tst-1/Oct-6 has been shown to positively regulate transcription from the α3 promoter in a cell-type-specific manner (Yang et al., 1994). Similar to PHOX2A, the POU domain factor SCIP/Tst-1/Oct-6 does not require DNA binding for trans-activation of the α3 promoter (Yang et al., 1994). Deletional analysis of the SCIP/Tst-1/Oct-6 transcription factor demonstrated that only the POU domain is needed for trans-activation. Interestingly, this trans-activation does not depend on the presence of an Sp1 motif in the promoter region and is likely occurring through protein-protein interactions with the basal transcription machinery (Fyodorov and Deneris, 1996). The transcription factor Brn-3a also trans-activates the α3 promoter, while the other members of the Brn-3 family, Brn-3b and 3c, modestly repress α3 promoter activity (Milton et al., 1996). The positive regulation by Brn-3a is thought to be a result of protein-protein interaction as the α3 promoter lacks an obvious octamer or octamer-related binding site for Brn-3 factors (Milton et al., 1996).

A transcriptional enhancer has been discovered upstream of the α3 promoter in a region that overlaps with a 3′-untranslated exon of the β4 gene (McDonough and Deneris, 1997). This transcriptional enhancer consists of two identical 37-base pair repeats separated by a 6-base pair spacer. The β4 3′ enhancer acts as a cell-type-specific enhancer and is capable of enhancing transcription from the α3 promoter in neuronal-like cells, as well as in neurons in SCG cultures (McDonough et al., 2000). The enhancer contains several E-twenty six (ETS) factor-binding sites, the mutation of which dramatically decreases, but does not completely abolish, α3 promoter activity. The ETS-domain binding factor, Pet-1, has been shown to activate reporter gene transcription in a manner that is both cell type- and β4 3′ enhancer-dependent (Fyodorov et al., 1998). Taken together, these experiments suggest that Pet-1 interacts directly with the α3 promoter to activate transcription, though it likely requires additional cell-type-specific cofactors. In vivo experiments using transgenic mice showed that a larger DNA fragment between the α3 and β4 genes, containing both the β4 3′ enhancer and the α3 promoter, is capable of directing expression of a reporter gene to several areas of endogenous α3 expression in the brain (Wada et al., 1989; Yang et al., 1997). Surprisingly however, this DNA fragment did not direct reporter gene expression anywhere in the peripheral nervous system, in which the α3 gene is highly expressed (see above), suggesting that elements in this fragment may be acting as repressors or that other sequences are necessary for peripheral expression.

The presence of an intronic repressor element in the fifth intron of α3 has in fact been reported (Fuentes Medel and Gardner, 2007). The sequence of this α3 intron 5 repressor (α3I5) is highly conserved and is capable of bidirectional repressor activity in vitro. Notably, cell-type-specific repression of promoter activity was observed to be more potent in non-neuronal cell lines than in neuronal cell lines (Fuentes Medel and Gardner, 2007). These data suggest that this segment of DNA and the factors with which it interacts function to restrict expression of α3 to neuronal cell types. The protein-DNA interactions that mediate this effect have yet to be elucidated.

While regulation of the α3 subunit gene in neuronal cells has been extensively studied, the mechanisms regulating α3 expression in non-neuronal cells remain largely obscure. Recently, however, our group was the first to report that a transcription factor, the achaete-scute complex homolog-1 (ASCL1), regulates the expression of α3 and β4 and modestly of α5 in lung cancer cells (Improgo et al., 2010).

3.2.2. CHRNA5

The α5 promoter region has been described in several genomic contexts including those in rodents and humans. Transcription of α5 occurs in the opposite direction as α3 and β4 (Fig. 1), suggesting that in addition to transcription factors that regulate the entire cluster, distinct mechanisms may govern α5 expression. However, apart from the regulatory factors described above that control expression of all three clustered genes, little is known about these mechanisms. SCIP/Tst-1/Oct-6 does not appear to regulate α5 though it regulates α3 and β4. Similarly, in lung cells, ASCL1 appears to regulate α3 and β4 but not α5 (Improgo et al., 2010). No other transcription factors regulating α5 expression have been reported, underscoring the need for more research effort in this area.

3.2.3. CHRNB4

In addition to the Sp factors, Sox10 and SCIP/Tst-1/Oct-6, the β4 promoter is positively regulated by c-Jun (Melnikova and Gardner, 2001). Trans-activation by all of these factors is abolished when the Sp-binding site on the β4 promoter (referred to as a CA box) is mutated. Conversely, synergistic activation of the β4 promoter is observed when Sp1 is supplied in concert with Sox10, Sp3 or c-Jun (Melnikova and Gardner, 2001; Melnikova et al., 2000a). Co-immunoprecipitation experiments demonstrated that all of these factors physically interact (Melnikova et al., 2000b) and ChIP experiments confirmed that these interactions occur in the context of native chromatin (Scofield et al., 2008). These findings suggest the existence of a positively-acting multi-subunit transcriptional regulatory complex that assembles on the β4 promoter. This result is consistent with the hypothesis that Sp1 is critical for transcription from the β4 promoter and likely nucleates the regulatory complex that drives expression of the β4 gene.

Two additional transcription factors have been shown to interact with the β4 promoter, Purα and heterogeneous nuclear ribonucleoprotein K (hnRNP K)(Du et al., 1998; Du et al., 1997). These proteins interact with another motif, the CT box, located directly upstream of the CA box. hnRNP K is capable of repressing Sp factor-mediated trans-activation of the β4 promoter (Du et al., 1998) and also physically interacts with Sox10 (Melnikova et al., 2000b). Similar to hnRNP K, Purα physically interacts with Sox10 (Melnikova et al., 2000b). Moreover, Purα and hnRNP K themselves physically interact (Melnikova et al., 2000b). These proteins may participate in the multi-subunit complex described above to modulate expression of the β4 gene in the appropriate cellular context. In vitro binding experiments demonstrated that each factor binds preferentially to the opposing single strand elements of the CT box, suggesting that some local DNA helix unwinding may occur (Krecic and Swanson, 1999). Interestingly, Purα and hnRNP K have been shown to function together to negatively impact transcription of genes in other systems and the same may be occurring at the β4 promoter (Da Silva et al., 2002). In vivo experiments have also shown that a 2.3-kb fragment of the β4 promoter, containing the CA and CT boxes, is capable of directing reporter gene expression to brain regions that endogenously express β4, further supporting the importance of these elements in regulating β4 gene expression (Bruschweiler-Li et al., 2010).

4. Role in Pathological States

4.1. Nicotine Addiction

Nicotine addiction is responsible for approximately 5 million deaths per year worldwide and is the most preventable cause of death in the USA (CDC, 2008). Nicotine addiction involves a series of events starting with the initial use of cigarettes, the transition from experimental smoking to regular smoking, and finally dependence on nicotine (Bierut, 2009b). Nicotine dependence is characterized by heavier smoking, early morning smoking, tolerance and withdrawal. Withdrawal symptoms account for the high incidence of relapse in people attempting to quit smoking (Kenny and Markou, 2001).

At the molecular level, nicotine addiction is initiated by the binding of nicotine to nAChRs. This interaction results in increased dopamine (DA) release in the DAergic mesolimbic and mesocortical circuits (Dani and De Biasi, 2001; Dani and Heinemann, 1996), a phenomenon widely associated with reward or reinforcement and drugs of abuse. DAergic projection neurons in the mesocorticolimbic pathway originate in the ventral tegmentum area (VTA) and project to the nucleus accumbens in the ventral striatum and the prefrontal cortex (Laviolette and van der Kooy, 2004). Several nAChR subtypes are robustly expressed in DAergic neurons both at the level of the soma, as well as at presynaptic terminals. Although, of the clustered nicotinic receptor subunit genes, α5 has been clearly identified as a component of nAChRs at DAergic terminals (Grady et al., 2007). Much of what is known regarding nAChR subtypes that are involved in nicotine addiction stems from studies on genetically engineered KO or knock-in mice (Champtiaux and Changeux, 2004). Mice that lack expression of β2* nAChRs fail to self-administer nicotine and exhibit impaired tolerance to nicotine (Maskos et al., 2005; McCallum et al., 2006; Picciotto et al., 1998). In addition, the predominant partner of the β2 nAChR subunit, α4 has also been implicated in nicotine dependence (Marubio et al., 2003; Tapper et al., 2007; Tapper et al., 2004). Selective activation of α4* nAChRs by low doses of nicotine in mice expressing α4* nAChRs hypersensitive to agonist is sufficient for nicotine reward/reinforcement, sensitization, and tolerance (Tapper et al., 2004). More recently, it was found that mice that do not express α6* nAChRs fail to self-administer nicotine (Pons et al., 2008). Expression of the α6 subunit has also been observed in the striatum and about half of α6* nAChRs co-assemble with α4 to form receptors with the highest affinity for ACh in the striatum (Champtiaux et al., 2002; Salminen et al., 2007). Because of their high expression in the reward pathway and high affinity for agonist, α4β2* nAChRs have been studied extensively in the context of nicotine addiction.

In recent years, linkage analyses, candidate-gene analyses, and large-scale genome-wide association studies (GWAS) have been used to screen hundreds of thousands of SNPs across thousands of individuals in search of genetic variants associated with nicotine dependence (Baker et al., 2009; Berrettini et al., 2008; Bierut, 2009a; Bierut et al., 2008; Caporaso et al., 2009; Chen et al., 2009a; Freathy et al., 2009; Greenbaum and Lerer, 2009; Grucza et al., 2008; Le Marchand et al., 2008; Saccone et al., 2009a; Saccone et al., 2009b; Saccone et al., 2007; Schlaepfer et al., 2008; Schwartz et al., 2009; Spitz et al., 2008; Stevens et al., 2008; Thorgeirsson et al., 2008; Vink et al., 2009; Wang et al., 2009a; Weiss et al., 2008). This has led to the identification of multiple SNPs in chromosome 15q24–25, a region that contains the CHRNA5/A3/B4 gene cluster as well as the iron-responsive element binding protein, a putative protein of unknown function, LOC123688, and the α4 proteasome subunit protein. Of particular interest is the non-synonymous SNP, rs16969968, found in exon5 of the α5 gene. This polymorphism changes an aspartic acid residue into asparagine at position 398 (D398N) in the second intracellular loop of α5. Individuals with one copy of the risk variant have a 1.3-fold increased risk for nicotine dependence while individuals with two copies have almost a 2-fold increase in risk. This SNP appears to influence different aspects of nicotine dependence, as it has been associated with increased risk for heavy smoking as well as increased sensitivity to the pleasurable effects of nicotine (Sherva et al., 2008; Stevens et al., 2008). In addition, the presence of this SNP may also influence the biophysical properties of α5* nAChRs. When expressed in HEK293T cells, α4β2α5D398 nAChRs exhibited a greater maximal response to nicotine compared to α4β2N398 nAChRs as measured by calcium imaging (Bierut et al., 2008). The association of this particular SNP has been identified in several studies though the majority of them have involved populations of European descent. In populations of African and Asian descent, the risk allele of rs16969968 is rare but is still associated with nicotine dependence (Saccone et al., 2009b; Wu et al., 2009).

How the clustered nAChRs function in the development of addiction is still unknown though recent studies in nAChR KO mice have revealed a potential role for these subunits in nicotine withdrawal. Withdrawal symptoms can be divided into two classes: somatic or physical symptoms, which likely involve both the PNS and CNS; and affective symptoms, which are centrally-mediated and are associated with hypoactivity of DAergic neurons in the reward circuit (Fung et al., 1996). As in humans, rodents chronically exposed to nicotine exhibit both somatic and affective withdrawal behaviors upon cessation. Somatic withdrawal symptoms in rodents are characterized by increased licking, grooming, shaking and scratching (Damaj et al., 2003; Kenny and Markou, 2001; Malin et al., 1994). Rodent affective symptoms include increased anxiety, hypolocomotion, and conditioned place aversion to nicotinic receptor antagonists (Damaj et al., 2003; Jackson et al., 2008a; Suzuki et al., 1996). The initiation and expression of withdrawal is dependent on neuronal nAChRs based on the fact that 1) symptoms can be alleviated by nicotine treatment and 2) symptoms can be precipitated by administration of nicotinic receptor antagonists during chronic nicotine exposure. Mecamylamine, a noncompetitive nicotinic antagonist, precipitates somatic withdrawal symptoms as well as affective symptoms including hypolocomotion, place aversion and anxiety, when injected i.p. in nicotine-dependent mice or rats (Damaj et al., 2003; Malin et al., 1994; Suzuki et al., 1999; Suzuki et al., 1996). The more selective high affinity nAChR competitive antagonist, dihydro-β–erythroidine (DHβE) (Harvey and Luetje, 1996; Harvey et al., 1996), can also precipitate both somatic and affective symptoms suggesting a role for high affinity nAChRs in withdrawal (Malin et al., 1998). Methyllycaconitine (MLA), a relatively selective α7 antagonist (Alkondon et al., 1992; Palma et al., 1996; Ward et al., 1990)(but see (Klink et al., 2001)), precipitates mild somatic, but few affective withdrawal symptoms (Markou and Paterson, 2001). Finally, somatic withdrawal symptoms can be precipitated by hexamethonium, a nicotinic antagonist that does not cross the blood brain barrier suggesting that peripheral nAChRs also play a role in these symptoms (Hildebrand et al., 1997) although similar symptoms can be elicited by injection of antagonist directly into the brain (Salas et al., 2009). Conversely, affective symptoms are not blocked by i.p. injection of hexamethonium indicating that they are mediated by central nAChRs (Hildebrand et al., 1997; Watkins et al., 2000).

Chronic nicotine-treated α5 and β4 KO mice display significantly milder mecamylamine-precipitated somatic withdrawal symptoms compared to WT mice (Salas et al., 2004b; Salas et al., 2009). In the CNS, α5 and β4* nAChRs are robustly expressed in the habenulo-interpeduncular pathway and direct infusion of mecamylamine into either the medial habenula or the interpeduncular nucleus can precipitate withdrawal in mice dependent on nicotine suggesting that the nAChRs in this pathway are critical for the expression of nicotine withdrawal (Salas et al., 2009). However, chronic nicotine treated α5 KO mice still become anxious during withdrawal suggesting that α5* nAChRs may not be involved in affective symptoms (Jackson et al., 2008b).

To date, the role of either α5* or β4* nAChRs in nicotine reward and reinforcement is unclear. Nicotine conditions a place preference in α5 KO mice indicating that expression of α5* nAChRs may not be necessary for the rewarding properties of the drug (Jackson et al., 2010). However, these animals not only exhibit a preference for nicotine at similar doses as WT mice, but also at high doses that normally fail to condition a place preference. Additional analysis of the reinforcing properties of nicotine in KO mice that do not express α5 or β4 nAChRs and/or in knock-in mice that express the α5 polymorphism identified in the GWAS should yield valuable insight into the molecular mechanisms underlying nicotine addiction.

4.2. Lung Cancer

Lung cancer is the leading cause of cancer-related deaths for both men and women worldwide (ACS, 2009). In terms of incidence, lung cancer is second only to prostate cancer in men and breast cancer in women. Lung cancer can be divided into two main histological types: small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC). The latter can be further divided into adenocarcinoma, squamous cell, bronchioalveolar and large cell lung carcinoma.

Tobacco intake is the main risk factor associated with lung cancer. The scientific link between tobacco and lung cancer has been firmly established since the 1950s (Proctor, 2001). This linkage is not surprising given 1) the addictive effects of nicotine that promote continued use of tobacco despite health consequences and 2) the presence of at least 55 carcinogens in tobacco, including nicotine metabolites such as 4-(methylnitrosamino)-1-(3-pyridyl)-butanone (NNK) and N-nitrosonornicotine (NNN)(Hecht, 1999; Shields, 2002). NNK and NNN form DNA adducts causing mutations that initiate cancer (Hecht and Hoffmann, 1988). Interestingly, these nitrosamines also serve as ligands for nAChRs (Schuller and Orloff, 1998) and along with nicotine and ACh, have been shown to trigger a variety of cancer-related processes as described below.

In 1989, Schuller’s group first showed that nicotine and its metabolites stimulates the growth of lung cancer cells (Schuller, 1989). Shortly thereafter, Minna’s group reported that nicotine causes apoptotic inhibition (Maneckjee and Minna, 1990). These two groups and many others thereafter have reported the expression of nAChRs in both normal and malignant lung cells, supporting the notion that nicotine stimulates cancer-related processes in a receptor-mediated fashion (Maneckjee and Minna, 1990; Maus et al., 1998; Sartelet et al., 2008; Schuller, 1989; Song et al., 2003; Wang et al., 2001). Moreover, studies have shown that specific nAChR subunits are over-expressed in lung cancer tissue (Lam et al., 2007). In particular, the CHRNA5/A3/B4 gene cluster is over-expressed in SCLC and this over-expression appears to be regulated by ASCL1 (Improgo et al., 2010). ASCL1 is a basic helix-loop-helix transcription factor important in the initiation and development of SCLC (Ball et al., 1993; Jiang et al., 2009; Linnoila et al., 2000; Osada et al., 2005). Regulation of the CHRNA5/A3/B5 locus by ASCL1 suggests a mechanism by which over-expression of ASCL1 in SCLC leads to a corresponding increase in expression of the clustered nAChR subunits, thereby potentiating the proliferative and pro-survival effects of nicotine and other nAChR ligands (Improgo et al., 2010).

Different groups have shown that various nAChR ligands activate distinct cancer-signaling pathways via the α3β2, α3β4, α4β2 and α7 nAChR subtypes (Schuller, 2009). ACh stimulates cell proliferation by acting as an autocrine growth factor in SCLC, a phenomenon that can be blocked by the non-specific nAChR antagonist, mecamylamine (Song et al., 2003). Nicotine also up-regulates the expression of growth factors and their cognate receptors (Conti-Fine et al., 2000). NNK causes cell proliferation by activating the serine/threonine kinase RAF1 and mitogen-activated protein kinase, leading to the activation of the oncogenic transcription factor c-myc, a process that can be blocked by the α7-selective antagonist, α-bungarotoxin (Jull et al., 2001). In addition, nicotine and NNK play a role in apoptotic inhibition. Nicotine activates the anti-apoptotic protein BCL-2 and inactivates the proapoptotic proteins Bad and Bax (Jin et al., 2004; Mai et al., 2003; Xin and Deng, 2005). Nicotine and NNK also activate the Akt/protein kinase B pathway, inhibiting apoptosis and causing tumorigenesis (West et al., 2003). Activation of Akt by nicotine appears to depend on nAChRs containing α3 or α4 whereas NNK activation depends on α7 nAChRs. Finally, nicotine acts as a pro-angiogenic agent, promoting endothelial cell migration, proliferation, tube formation and survival, an effect antagonized by α-bungarotoxin (Cooke and Ghebremariam, 2008; Heeschen et al., 2001). Along with its metabolite, cotinine, nicotine also up-regulates the expression of the vascular endothelial growth factor in endothelial cells (Conklin et al., 2002).

The aforementioned candidate-gene analyses and GWAS have also implicated the CHRNA5/A3/B4 gene cluster in lung cancer. The same SNP associated with nicotine dependence was found to increase the risk for lung cancer (Amos et al., 2008; Hung et al., 2008; Thorgeirsson et al., 2008). In particular, Hung and colleagues analyzed approximately 317,000 SNPs in thousands of patients and controls and found that the non-synonymous SNP, rs16969968, is robustly associated with lung cancer. This association was not affected by smoking status and was observed even in never-smoker groups, suggesting that the association is not due to the influence of nicotine dependence. Furthermore, no increased risk for other smoking-related cancers such as head and neck cancers was observed, indicating that the association with lung cancer is direct (Hung et al., 2008). Two other SNPs, in exon 5 and the 3′-untranslated region of the α3 gene, were also found in these studies to be associated with lung cancer (Amos et al., 2008; Hung et al., 2008; Thorgeirsson et al., 2008).

4.3 Other Diseases

Aside from nicotine addiction and lung cancer, the CHRNA5/A3/B4 locus has also been associated with alcoholism. SNPs in this locus are associated with alcohol dependence and the level of response to alcohol (Chen et al., 2009b; Wang et al., 2009b). Furthermore, the variants appear to influence age at initiation of both tobacco and alcohol use (Schlaepfer et al., 2008). Since alcohol and nicotine are usually co-abused, these associations may provide a genetic mechanism for this co-morbidity (Greenbaum and Lerer, 2009). The risk allele of the non-synonymous SNP, rs16969968, also appears to be protective for cocaine dependence, suggesting a more general involvement of the CHRNA5/A3/B4 gene cluster in the actions of drugs of abuse (Grucza et al., 2008).

Other smoking-related diseases are influenced by variants in the CHRNA5/A3/B4 locus. Two SNPs in this region are associated with chronic obstructive pulmonary disease, a serious lung disease characterized by chronic inflammation and progressive destruction of lung tissues (Pillai et al., 2009). Interestingly, nicotine has been shown to promote the development of SCLC-like tumors in a rodent model of chronic obstructive pulmonary disease (Schuller et al., 1995). Another study showed that a variant influencing the risk for nicotine dependence and lung cancer also increases the risk for peripheral arterial disease, a condition characterized by obstruction of arteries outside the heart and brain (Thorgeirsson et al., 2008). The association of variants in the CHRNA5/A3/B4 gene cluster on other smoking-related diseases may be an effect of nicotine dependence, suggesting a gene-environment interaction, or may represent a direct effect, indicating pleiotropy of this locus (Bierut, 2009a; Thorgeirsson et al., 2008).

5. Conclusions

Tobacco use continues to be a major global health threat, underscoring the need to understand the mechanisms leading to nicotine dependence and smoking-related diseases such as lung cancer. Nicotine activation of nAChRs in the CNS initiates nicotine dependence. However, it is clear that nAChRs are also expressed outside the nervous system and are likely involved in numerous smoking-related pathologies. Although most studies to date have implicated the high affinity α4β2* nAChRs in nicotine dependence, less is known regarding the role of α3α5β4* nAChRs in this disease (Picciotto et al., 1998; Tapper et al., 2004). However, the recent flurry of GWAS implicating the CHRNA5/A3/B4 gene cluster in nicotine dependence lends greater credence to the involvement of these hitherto understudied nAChR subunits in nicotine addiction (Berrettini et al., 2008; Bierut et al., 2008; Portugal and Gould, 2008; Saccone et al., 2009a; Saccone et al., 2007; Schlaepfer et al., 2008). That results of both hypothesis-free GWAS and hypothesis-driven candidate-gene studies converged on this gene cluster is particularly compelling. These studies underscore the importance of elucidating the mechanism by which α3α5β4* nAChRs may modulate nicotine-mediated behaviors. In particular, future studies should examine nicotine self-administration in the existing mouse nAChR KO models as well as in knock-in mice expressing the polymorphisms identified in the GWAS.

Even more provoking are similar studies implicating this gene cluster in lung cancer (Amos et al., 2008; Hung et al., 2008; Thorgeirsson et al., 2008). It is still somewhat controversial, however, as to whether the association with lung cancer is direct or merely a by-product of the strength of the addiction or smoking behavior (Chanock and Hunter, 2008). As discussed in this Review, several lines of evidence support the hypothesis of a direct role of nAChRs in lung cancer. In particular, a number of pharmacology-based studies have demonstrated that nAChR activation can initiate a variety of signal transduction cascades associated with cancer (Schuller, 2009). However, it is important to acknowledge that the currently available pharmacological reagents used in these studies, while selective, are not specific, thus care must be taken when interpreting the results. This is a particularly important point with respect to the CHRNA5/A3/B4 cluster, for which the availability of selective ligands is extremely limited. Thus, design of highly specific nAChR ligands is of prime importance. Alternatively, studies using RNA interference and knockout/knock-in mouse models should help elucidate the function of specific nAChR subtypes in lung cancer.

Determining the role of the CHRNA5/A3/B4 cluster in nicotine dependence and lung cancer is important for the rational design of therapeutic interventions. In particular, the use of nAChR ligands as smoking cessation therapies have to take into consideration the possible effects of these drugs on lung cancer.

Table 3
Transcription Factors that Regulate the CHRNA5/A3/B4 Genes

Acknowledgments

Work in the authors’ laboratories is supported in part by grant R01NS030243 (PDG) and R01AA017656 (ART) from the National Institutes of Health.

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References

  • ACS. Cancer Facts and Figures 2009. American Cancer Society. 2009:1–68.
  • Albuquerque EX, Pereira EF, Alkondon M, Rogers SW. Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev. 2009;89:73–120. [PMC free article] [PubMed]
  • Alkondon M, Pereira EF, Wonnacott S, Albuquerque EX. Blockade of nicotinic currents in hippocampal neurons defines methyllycaconitine as a potent and specific receptor antagonist. Mol Pharmacol. 1992;41:802–808. [PubMed]
  • Amos CI, Wu X, Broderick P, Gorlov IP, Gu J, Eisen T, Dong Q, Zhang Q, Gu X, Vijayakrishnan J, Sullivan K, Matakidou A, Wang Y, Mills G, Doheny K, Tsai Y-Y, Chen WV, Shete S, Spitz MR, Houlston RS. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet. 2008;40:616–622. [PMC free article] [PubMed]
  • Arneric SP, Holladay M, Williams M. Neuronal nicotinc receptors: A perspective on two decades of drug discovery research. Biochem Pharmacol. 2007;74:1092–1101. [PubMed]
  • Arredondo J, Chernyavsky AI, Marubio LM, Beaudet AL, Jolkovsky DL, Pinkerton KE, Grando SA. Receptor-mediated tobacco toxicity: Regulation of gene expression through α3β2 nicotinic receptor in oral epithelial cells. Am J Pathol. 2005;166:597–613. [PubMed]
  • Arredondo J, Nguyen VT, Chernyavsky AI, Jolkovsky DL, Pinkerton KE, Grando SA. A receptor-mediated mechanism of nicotine toxicity in oral keratinocytes. Lab Invest. 2001;81:1653–1668. [PubMed]
  • Azam L, Winzer-Serhan UH, Chen Y, Leslie FM. Expression of neuronal nicotinic acetylcholine receptor subunit mRNAs within midbrain dopamine neurons. J Comp Neurol. 2002;444:260–274. [PubMed]
  • Baker TB, Weiss RB, Bolt D, von Niederhausern A, Fiore MC, Dunn DM, Piper ME, Matsunami N, Smith SS, Coon H, McMahon WM, Scholand MB, Singh N, Hoidal JR, Kim SY, Leppert MF, Cannon DS. Human neuronal acetylcholine receptor A5-A3-B4 haplotypes are associated with multiple nicotine dependence phenotypes. Nicotine Tob Res. 2009;11:785–796. [PMC free article] [PubMed]
  • Ball DW, Azzoli CG, Baylin SB, Chi D, Dou S, Donis-Keller H, Cumaraswamy A, Borges M, Nelkin BD. Identification of a human achaete-scute homolog highly expressed in neuroendocrine tumors. Proc Natl Acad Sci U S A. 1993;90:5648–5652. [PubMed]
  • Bansal A, Singer JH, Hwang BJ, Xu X, Beaudet A, Feller MB. Mice lacking specific nicotinic acetylcholine receptor subunits exhibit dramatically altered spontaneous activity patterns and reveal a limited role for retinal waves in forming ON and OFF circuits in the inner retina. J Neurosci. 2000;20:7672–7681. [PubMed]
  • Barnard EA, Miledi R, Sumikawa K. Translation of exogenous messenger RNA coding for nicotinic acetylcholine receptors produces functional receptors in Xenopus oocytes. Proc R Soc Lond B Biol Sci. 1982;215:241–246. [PubMed]
  • Battaglioli E, Gotti C, Terzano S, Flora A, Clementi F, Fornasari D. Expression and transcriptional regulation of the human alpha3 neuronal nicotinic receptor subunit in T lymphocyte cell lines. J Neurochem. 1998;71:1261–1270. [PubMed]
  • Benfante R, Flora A, Di Lascio S, Cargnin F, Longhi R, Colombo S, Clementi F, Fornasari D. Transcription factor PHOX2A regulates the human α3 nicotinic receptor subunit gene promoter. J Biol Chem. 2007;282:13290–13302. [PubMed]
  • Benhammou K, Lee M, Strook M, Sullivan B, Logel J, Raschen K, Gotti C, Leonard S. [(3)H]Nicotine binding in peripheral blood cells of smokers is correlated with the number of cigarettes smoked per day. Neuropharmacology. 2000;39:2818–2829. [PubMed]
  • Berrettini W, Yuan X, Tozzi F, Song K, Francks C, Chilcoat H, Waterworth D, Muglia P, Mooser V. α-5/α-3 nicotinic receptor subunit alleles increase risk for heavy smoking. Mol Psych. 2008;13:368–373. [PMC free article] [PubMed]
  • Bierut LJ. Convergence of genetic findings for nicotine dependence and smoking related diseases with chromosome 15q24–25. Trends Pharmacol Sci. 2009a;31:46–51. [PMC free article] [PubMed]
  • Bierut LJ. Nicotine dependence and genetic variation in the nicotinic receptors. Drug Alcohol Depend. 2009b;104(Suppl 1):S64–69. [PMC free article] [PubMed]
  • Bierut LJ, Stitzel JA, Wang JC, Hinrichs AL, Grucza RA, Xuei X, Saccone SF, Bertelsen S, Fox L, Horton WJ, Breslau N, Budde J, Cloninger CR, Dick DM, Foroud T, Hatsukami D, Hesselbrock V, Johnson EO, Kuperman S, Madden PAF, Mayo K, Nurnberger J, Pomerleau O, Porjesz B, Reyes O, Schuckit M, Swan G, Tischfield JA, Edenberg HJ, Rice JP, Goate AM. Variants in nicotinic receptors and risk for nicotine dependence. Am J Psychiatry. 2008;165:1163–1171. [PMC free article] [PubMed]
  • Bigger CB, Casanova EA, Gardner PD. Transcriptional regulation of neuronal nicotinic acetylcholine receptor genes. Functional interactions between Sp1 and the rat beta4 subunit gene promoter. J Biol Chem. 1996;271:32842–32848. [PubMed]
  • Bigger CB, Melnikova IN, Gardner PD. Sp1 and Sp3 regulate expression of the neuronal nicotinic acetylcholine receptor β4 subunit gene. J Biol Chem. 1997;272:25976–25982. [PubMed]
  • Boulter J, Connolly J, Deneris E, Goldman D, Heinemann S, Patrick J. Functional expression of two neuronal nicotinic acetylcholine receptors from cDNA clones identifies a gene family. Proc Natl Acad Sci U S A. 1987;84:7763–7767. [PubMed]
  • Boulter J, O’Shea-Greenfield A, Duvoisin RM, Connolly JG, Wada E, Jensen A, Gardner PD, Ballivet M, Deneris ES, McKinnon D, et al. Alpha 3, alpha 5, and beta 4: three members of the rat neuronal nicotinic acetylcholine receptor-related gene family form a gene cluster. J Biol Chem. 1990;265:4472–4482. [PubMed]
  • Boyd RT. Transcriptional regulation and cell specificity determinants of the rat nicotinic acetylcholine receptor alpha 3 gene. Neurosci Lett. 1996;208:73–76. [PubMed]
  • Boyd RT, Jacob MH, McEachern AE, Caron S, Berg DK. Nicotinic acetylcholine receptor mRNA in dorsal root ganglion neurons. J Neurobiol. 1991;22:1–14. [PubMed]
  • Brejc K, van Dijk WJ, Klaassen RV, Schuurmans M, van Der Oost J, Smit AB, Sixma TK. Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors. Nature. 2001;411:269–276. [PubMed]
  • Bruschweiler-Li L, Fuentes Medel YF, Scofield MD, Trang EBT, Binke SA, Gardner PD. Temporally- and spatially-regulated transcriptional activity of the nicotinic acetylcholine receptor β4 subunit gene promoter region. Neurosci. 2010;166:864–877. [PMC free article] [PubMed]
  • Campos-Caro A, Carrasco-Serrano C, Valor LM, Ballesta JJ, Criado M. Activity of the nicotinic acetylcholine receptor alpha5 and alpha7 subunit promoters in muscle cells. DNA Cell Biol. 2001;20:657–666. [PubMed]
  • Campos-Caro A, Carrasco-Serrano C, Valor LM, Viniegra S, Ballesta JJ, Criado M. Multiple functional Sp1 domains in the minimal promoter region of the neuronal nicotinic receptor alpha5 subunit gene. J Biol Chem. 1999;274:4693–4701. [PubMed]
  • Caporaso N, Gu F, Chatterjee N, Sheng-Chih J, Yu K, Yeager M, Chen C, Jacobs K, Wheeler W, Landi MT, Ziegler RG, Hunter DJ, Chanock S, Hankinson S, Kraft P, Bergen AW. Genome-wide and candidate gene association study of cigarette smoking behaviors. PLoS One. 2009;4:e4653. [PMC free article] [PubMed]
  • Catassi A, Servent D, Paleari L, Cesario A, Russo P. Multiple roles of nicotine on cell proliferation and inhibition of apoptosis: implications on lung carcinogenesis. Mutat Res. 2008;659:221–231. [PubMed]
  • CDC. Cigarette smoking among adults - United States, 2007. Morbidity and Mortality Weekly Report. 2008;57:1221–1226. [PubMed]
  • Champtiaux N, Changeux JP. Knockout and knockin mice to investigate the role of nicotinic receptors in the central nervous system. Prog Brain Res. 2004;145:235–251. [PubMed]
  • Champtiaux N, Han ZY, Bessis A, Rossi FM, Zoli M, Marubio L, McIntosh JM, Changeux JP. Distribution and pharmacology of alpha 6-containing nicotinic acetylcholine receptors analyzed with mutant mice. J Neurosci. 2002;22:1208–1217. [PubMed]
  • Chanock SJ, Hunter DJ. When the smoke clears … Nature. 2008;452:537–538. [PubMed]
  • Chen D, Tian T, Wang H, Liu H, Hu Z, Wang Y, Liu Y, Ma H, Fan W, Miao R, Sun W, Wang Y, Qian J, Jin L, Wei Q, Shen H, Huang W, Lu D. Association of human aryl hydrocarbon receptor gene polymorphisms with risk of lung cancer among cigarette smokers in a Chinese population. Pharmacogenet Genomics. 2009a;19:25–34. [PubMed]
  • Chen X, Chen J, Williamson VS, An SS, Hettema JM, Aggen SH, Neale MC, Kendler KS. Variants in nicotinic acetylcholine receptors alpha5 and alpha3 increase risks to nicotine dependence. Am J Med Genet B Neuropsychiatr Genet. 2009b;150B:926–933. [PMC free article] [PubMed]
  • Conklin BS, Zhao W, Zhong DS, Chen C. Nicotine and cotinine up-regulate vascular endothelial growth factor expression in endothelial cells. Am J Pathol. 2002;160:413–418. [PubMed]
  • Conroy WG, Berg DK. Neurons can maintain multiple classes of nicotinic acetylcholine receptors distinguished by different subunit compositions. J Biol Chem. 1995;270:4424–4431. [PubMed]
  • Conti-Fine BM, Navaneetham D, Lei S, Maus AD. Neuronal nicotinic receptors in non-neuronal cells: new mediators of tobacco toxicity? Eur J Pharmacol. 2000;393:279–294. [PubMed]
  • Conti-Tronconi BM, McLane KE, Raftery MA, Grando SA, Protti MP. The nicotinic acetylcholine receptor: Structure and autoimmune pathology. Crit Rev Biochem Mol Biol. 1994;29:69–123. [PubMed]
  • Cooke JP, Ghebremariam YT. Endothelial nicotinic acetylcholine receptors and angiogenesis. Trends Cardiovasc Med. 2008;18:247–253. [PMC free article] [PubMed]
  • Cooper E, Couturier S, Ballivet M. Pentameric structure and subunit stoichiometry of a neuronal nicotinic acetylcholine receptor. Nature. 1991;350:235–238. [PubMed]
  • Corringer PJ, Le Novere N, Changeux JP. Nicotinic receptors at the amino acid level. Annu Rev Pharmacol Toxicol. 2000;40:431–458. [PubMed]
  • Corriveau RA, Berg DK. Coexpression of multiple acetylcholine receptor genes in neurons: quantitation of transcripts during development. J Neurosci. 1993;13:2662–2671. [PubMed]
  • Couturier S, Bertrand D, Matter JM, Hernandez MC, Bertrand S, Millar N, Valera S, Barkas T, Ballivet M. A neuronal nicotinic acetylcholine receptor subunit (alpha 7) is developmentally regulated and forms a homo-oligomeric channel blocked by alpha-BTX. Neuron. 1990a;5:847–856. [PubMed]
  • Couturier S, Erkman L, Valera S, Rungger D, Bertrand S, Boulter J, Ballivet M, Bertrand D. Alpha 5, alpha 3, and non-alpha 3. Three clustered avian genes encoding neuronal nicotinic acetylcholine receptor-related subunits. J Biol Chem. 1990b;265:17560–17567. [PubMed]
  • Covernton PJ, Kojima H, Sivilotti LG, Gibb AJ, Colquhoun D. Comparison of neuronal nicotinic receptors in rat sympathetic neurons with subunit pairs in Xenopus oocytes. J Physiol. 1994;481:27–34. [PubMed]
  • Da Silva N, Bharti A, Shelley CS. hnRNP-K and Purα act together to repress the transcriptional activity of the CD43 gene promoter. Blood. 2002;100:3536–3544. [PubMed]
  • Damaj MI, Kao W, Martin BR. Characterization of spontaneous and precipitated nicotine withdrawal in the mouse. J Pharmacol Exp Ther. 2003;307:526–534. [PubMed]
  • Dani JA, Bertrand D. Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu Rev Pharmacol Toxicol. 2007;47:699–729. [PubMed]
  • Dani JA, De Biasi M. Cellular mechanisms of nicotine addiction. Pharmacol Biochem Behav. 2001;70:439–446. [PubMed]
  • Dani JA, Heinemann S. Molecular and cellular aspects of nicotine abuse. Neuron. 1996;16:905–908. [PubMed]
  • De Fusco M, Becchetti A, Patrignani A, Annesi G, Gambardella A, Quattrone A, Ballabio A, Wanke E, Casari G. The nicotinic receptor beta 2 subunit is mutant in nocturnal frontal lobe epilepsy. Nat Genet. 2000;26:275–276. [PubMed]
  • Di Angelantonio S, Matteoni C, Fabbretti E, Nistri A. Molecular biology and electrophysiology of neuronal nicotinic receptors of rat chromaffin cells. Eur J Neurosci. 2003;17:2313–2322. [PubMed]
  • Dineley-Miller K, Patrick J. Gene transcripts for the nicotinic acetylcholine receptor subunit, beta4, are distributed in multiple areas of the rat central nervous system. Brain Res Mol Brain Res. 1992;16:339–344. [PubMed]
  • Du Q, Melnikova IN, Gardner PD. Differential effects of heterogeneous nuclear ribonucleoprotein K on Sp1- and Sp3-mediated transcriptional activation of a neuronal nicotinic acetylcholine receptor promoter. J Biol Chem. 1998;273:19877–19883. [PubMed]
  • Du Q, Tomkinson AE, Gardner PD. Transcriptional regulation of neuronal nicotinic acetylcholine receptor genes. A possible role for the DNA-binding protein Puralpha. J Biol Chem. 1997;272:14990–14995. [PubMed]
  • Egleton RD, Brown KC, Dasgupta P. Nicotinic acetylcholine receptors in cancer: multiple roles in proliferation and inhibition of apoptosis. Trends Pharmacol Sci. 2008;29:151–158. [PubMed]
  • Eisele JL, Bertrand S, Galzi JL, Devillers-Thiery A, Changeux JP, Bertrand D. Chimaeric nicotinic-serotonergic receptor combines distinct ligand binding and channel specificities. Nature. 1993;366:479–483. [PubMed]
  • Feller MB. The role of nAChR-mediated spontaneous retinal activity in visual system development. J Neurobiol. 2002;53:556–567. [PubMed]
  • Fischer H, Orr-Urtreger A, Role LW, Huck S. Selective deletion of the alpha5 subunit differentially affects somatic-dendritic versus axonally targeted nicotinic ACh receptors in mouse. J Physiol. 2005;563:119–137. [PubMed]
  • Flora A, Schulz R, Benfante R, Battaglioli E, Terzano S, Clementi F, Fornasari D. Neuronal and extraneuronal expression and regulation of the human alpha5 nicotinic receptor subunit gene. J Neurochem. 2000a;75:18–27. [PubMed]
  • Flora A, Schulz R, Benfante R, Battaglioli E, Terzano S, Clementi F, Fornasari D. Transcriptional regulation of the human alpha5 nicotinic receptor subunit gene in neuronal and non-neuronal tissues. Eur J Pharmacol. 2000b;393:85–95. [PubMed]
  • Flores CM, DeCamp RM, Kilo S, Rogers SW, Hargreaves KM. Neuronal nicotinic rceptor expression in sensory neurons of the rat trigeminal ganglion: Demonstration of α3/β4, a novel subtype in the mammalian nervous system. J Neuroscience. 1996;16:7892–7901. [PubMed]
  • Freathy RM, Ring SM, Shields B, Galobardes B, Knight B, Weedon MN, Smith GD, Frayling TM, Hattersley AT. A common genetic variant in the 15q24 nicotinic acetylcholine receptor gene cluster (CHRNA5-CHRNA3-CHRNB4) is associated with a reduced ability of women to quit smoking in pregnancy. Hum Mol Genet. 2009;18:2922–2927. [PMC free article] [PubMed]
  • Fuentes Medel YF, Gardner PD. Transcriptional repression by a conserved intronic sequence in the nicotinic receptor α3 subunit gene. J Biol Chem. 2007;282:19062–19070. [PubMed]
  • Fung YK, Schmid MJ, Anderson TM, Lau YS. Effects of nicotine withdrawal on central dopaminergic systems. Pharmacol Biochem Behav. 1996;53:635–640. [PubMed]
  • Fyodorov D, Deneris E. The POU domain of SCIP/Tst-1/Oct-6 is sufficient for activation of an acetylcholine receptor promoter. Mol Cell Biol. 1996;16:5004–5014. [PMC free article] [PubMed]
  • Fyodorov D, Nelson T, Deneris E. Pet-1, a novel ETS domain factor that can activate neuronal nAchR gene transcription. J Neurobiol. 1998;34:151–163. [PubMed]
  • Gahring LC, Persiyanov K, Dunn D, Weiss R, Meyer EL, Rogers SW. Mouse strain-specific nicotinic acetylcholine receptor expression by inhibitory interneurons and astrocytes in the dorsal hippocampus. J Comp Neurol. 2004a;468:334–346. [PubMed]
  • Gahring LC, Persiyanov K, Rogers SW. Neuronal and astrocyte expression of nicotinic receptor subunit beta4 in the adult mouse brain. J Comp Neurol. 2004b;468:322–333. [PubMed]
  • Gahring LC, Rogers SW. Neuronal nicotinic acetylcholine receptor expression and function on nonneuronal cells. AAPS Journal. 2006;7:E885–E894. [PMC free article] [PubMed]
  • Genzen JR, Van Cleve W, McGehee DS. Dorsal root ganglion neurons express multiple nicotinic acetylcholine receptor subtypes. J Neurophysiol. 2001;86:1773–1782. [PubMed]
  • Gerzanich V, Anand R, Lindstrom J. Homomers of alpha 8 and alpha 7 subunits of nicotinic receptors exhibit similar channel but contrasting binding site properties. Mol Pharmacol. 1994;45:212–220. [PubMed]
  • Gerzanich V, Wang F, Kuryatov A, Lindstrom J. alpha 5 Subunit alters desensitization, pharmacology, Ca++ permeability and Ca++ modulation of human neuronal alpha 3 nicotinic receptors. J Pharmacol Exp Ther. 1998;286:311–320. [PubMed]
  • Glushakov AV, Voytenko LP, Skok MV, Skok V. Distribution of neuronal nicotinic acetylcholine receptors containing different alpha-subunits in the submucosal plexus of the guinea-pig. Auton Neurosci. 2004;110:19–26. [PubMed]
  • Gotti C, Clementi F. Neuronal nicotinic receptors: from structure to pathology. Prog Neurobiol. 2004;74:363–396. [PubMed]
  • Gotti C, Moretti M, Gaimarri A, Zanardi A, Clementi F, Zoli M. Heterogeneity and complexity of native brain nicotinic receptors. Biochem Pharmacol. 2007;74:1102–1111. [PubMed]
  • Grady SR, Moretti M, Zoli M, Marks MJ, Zanardi A, Pucci L, Clementi F, Gotti C. Rodent habenulo-interpeduncular pathway expresses a large variety of uncommon nAChR subtypes, but only the α3β4* and α3β3β4* subtypes mediate acetylcholine release. J Neurosci. 2009;29:2272–2282. [PMC free article] [PubMed]
  • Grady SR, Salminen O, Laverty DC, Whiteaker P, McIntosh JM, Collins AC, Marks MJ. The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum. Biochem Pharmacol. 2007;74:1235–1246. [PMC free article] [PubMed]
  • Greenbaum L, Lerer B. Differential contribution of genetic variation in multiple brain nicotinic cholinergic receptors to nicotine dependence: recent progress and emerging open questions. Mol Psychiatry. 2009;14:912–945. [PubMed]
  • Groot-Kormelink PJ, Boorman JP, Sivilotti LG. Formation of functional alpha3beta4alpha5 human neuronal nicotinic receptors in Xenopus oocytes: a reporter mutation approach. Br J Pharmacol. 2001;134:789–796. [PubMed]
  • Grucza RA, Wang JC, Stitzel JA, Hinrichs AL, Saccone SF, Saccone NL, Bucholz KK, Cloninger CR, Neuman RJ, Budde JP, Fox L, Bertelsen S, Kramer J, Hesselbrock V, Tischfield J, Nurnberger JI, Almasy L, Porjesz B, Kuperman S, Schuckit MA, Edenberg HJ, Rice JP, Goate AM, Bierut LJ. A risk allele for nicotine dependence in CHRNA5 is a protective allele for cocaine dependence. Biol Psychiatry. 2008;64:922–929. [PMC free article] [PubMed]
  • Guan ZZ, Nordberg A, Mousavi M, Rinne JO, Hellström-Lindahl E. Selective changes in the levels of nicotinic acetylcholine receptor protein and of corresponding mRNA species in the brains of patients with Parkinson’s disease. Brain Res. 2002;956:358–366. [PubMed]
  • Harvey SC, Luetje CW. Determinants of competitive antagonist sensitivity on neuronal nicotinic receptor beta subunits. J Neurosci. 1996;16:3798–3806. [PubMed]
  • Harvey SC, Maddox FN, Luetje CW. Multiple determinants of dihydro-beta-erythroidine sensitivity on rat neuronal nicotinic receptor alpha subunits. J Neurochem. 1996;67:1953–1959. [PubMed]
  • Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst. 1999;91:1194–1210. [PubMed]
  • Hecht SS, Hoffmann D. Tobacco-specific nitrosamines, an important group of carcinogens in tobacco and tobacco smoke. Carcinogenesis. 1988;9:875–884. [PubMed]
  • Heeschen C, Jang JJ, Weis M, Pathak A, Kaji S, Hu RS, Tsao PS, Johnson FL, Cooke JP. Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis. Nat Med. 2001;7:833–839. [PubMed]
  • Hellström-Lindahl E, Gorbounova O, Seiger Å, Mousavi M, Nordberg A. Regional distribution of nicotinic receptors during prenatal development of human brain and spinal cord. Develop Brain Res. 1998;108:147–160. [PubMed]
  • Hellström-Lindahl E, Mousavi M, Zhang X, Ravid R, Nordberg A. Regional distribution of nicotinic receptor subunit mRNAs in human brain: comparison between Alzheimer and normal brain. Brain Res Mol Brain Res. 1999;66:94–103. [PubMed]
  • Hildebrand BE, Nomikos GG, Bondjers C, Nisell M, Svensson TH. Behavioral manifestations of the nicotine abstinence syndrome in the rat: peripheral versus central mechanisms. Psychopharmacology (Berl) 1997;129:348–356. [PubMed]
  • Hu HZ, Li ZW. Modulation of nicotinic ACh-, GABAA- and 5-HT3-receptor functions by external H-7, a protein kinase inhibitor, in rat sensory neurones. Br J Pharmacol. 1997;122:1195–1201. [PubMed]
  • Hu M, Liu QS, Chang KT, Berg DK. Nicotinic regulation of CREB activation in hippocampal neurons by glutamatergic and nonglutamatergic pathways. Mol Cell Neurosci. 2002;21:616–625. [PubMed]
  • Hung RJ, McKay JD, Gaborieau V, Boffetta P, Hashibe M, Zaridze D, Mukeria A, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Mates D, Bencko V, Foretova L, Janout V, Chen C, Goodman G, Field JK, Liloglou T, Xinarianos G, Cassidy A, McLaughlin J, Liu G, Narod S, Krokan HE, Skorpen F, Elvestad MB, Hveem K, Vatten L, Linseisen J, Clavel-Chapelon F, Vineis P, Bueno-de-Mesquita HB, Lund E, Martinez C, Bingham S, Rasmuson T, Hainaut P, Riboli E, Ahrens W, Benhamou S, Lagiou P, Trichopoulos D, Holcátová H, Merletti F, Kjaerheim K, Agudo A, Macfarlane G, Talamini R, Simonato L, Lowry R, Conway DI, Znaor A, Healy C, Zelenika D, Boland A, Delepine M, Foglio M, Lechner D, Matsuda F, Blanche H, Gut I, Heath S, Lathrop M, Brennan P. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature. 2008;452:633–637. [PubMed]
  • Improgo MRD, Schlichting NA, Cortes RY, Zhao-Shea R, Tapper AR, Gardner PD. ASCL1 regulates the expression of the CHRNA5/A3/B4 lung cancer susceptibility locus. Mol Cancer Res. 2010;8:194–203. [PMC free article] [PubMed]
  • Isacson O, Seo H, Lin L, Albeck D, Granholm AC. Alzheimer’s disease and Down’s syndrome: roles of APP, trophic factors and ACh. Trends Neurosci. 2002;25:79–84. [PubMed]
  • Jackson KJ, Marks MJ, Vann RE, Chen X, Gamage TF, Warner JA, Damaj MI. The role of α5 nicotinic acetylcholine receptors in the pharmacological and behavioral effects of nicotine in mice. J Pharmacol Exp Ther. 2010 Apr 16; [Epub ahead of print] [PubMed]
  • Jackson KJ, Martin BR, Changeux JP, Damaj MI. Differential role of nicotinic acetylcholine receptor subunits in physical and affective nicotine withdrawal signs. J Pharmacol Exp Ther. 2008a;325:302–312. [PMC free article] [PubMed]
  • Jackson KJ, Martin BR, Changeux JP, Damaj MI. Differential role of nicotinic acetylcholine receptor subunits in physical and affective nicotine withdrawal signs. J Pharmacol Exp Ther 2008b [PMC free article] [PubMed]
  • Ji D, Lape R, Dani JA. Timing and location of nicotinic activity enhances or depresses hippocampal synaptic plasticity. Neuron. 2001;31:131–141. [PubMed]
  • Jiang T, Collins BJ, Jin N, Watkins DN, Brock MV, Matsui W, Nelkin BD, Ball DW. Achaete-scute complex homologue 1 regulates tumor-initiating capacity in human small cell lung cancer. Cancer Res. 2009;69:845–854. [PMC free article] [PubMed]
  • Jin Z, Gao F, Flagg T, Deng X. Nicotine induces multi-site phosphorylation of Bad in association with suppression of apoptosis. J Biol Chem. 2004;279:23837–23844. [PubMed]
  • Jull BA, Plummer HK, 3rd , Schuller HM. Nicotinic receptor-mediated activation by the tobacco-specific nitrosamine NNK of a Raf-1/MAP kinase pathway, resulting in phosphorylation of c-myc in human small cell lung carcinoma cells and pulmonary neuroendocrine cells. J Cancer Res Clin Oncol. 2001;127:707–717. [PubMed]
  • Karlin A. Emerging structure of the nicotinic acetylcholine receptors. Nat Rev Neurosci. 2002;3:102–114. [PubMed]
  • Kawashima K, Fujii T. The lymphocytic cholinergic system and its contribution to the regulation of immune activity. Life Sci. 2003;74:675–696. [PubMed]
  • Kedmi M, Beaudet AL, Orr-Urtreger A. Mice lacking neuronal nicotinic acetylcholine receptor β4-subunit and mice lacking both α5- and β4-subunits are highly resistant to nicotine-induced seizures. Physiol Genomics. 2004;17:221–229. [PubMed]
  • Keiger CJH, Prevette D, Conroy WG, Oppenheim RW. Developmental expression of nicotinic receptors in the chick and human spinal cord. J Comp Neurol. 2003;455:86–99. [PubMed]
  • Kenny PJ, Markou A. Neurobiology of the nicotine withdrawal syndrome. Pharmacol Biochem Behav. 2001;70:531–549. [PubMed]
  • Klink R, de Kerchove d’Exaerde A, Zoli M, Changeux JP. Molecular and physiological diversity of nicotinic acetylcholine receptors in the midbrain dopaminergic nuclei. J Neurosci. 2001;21:1452–1463. [PubMed]
  • Krecic AM, Swanson MS. hnRNP complexes: composition, structure, and function. Curr Opin Cell Biol. 1999;11:363–371. [PubMed]
  • Lam DC, Girard L, Ramirez R, Chau W, Suen W, Sheriden S, Tin VPC, Chung L, Wong MP, Shay JW, Gazdar AF, Lam W, Minna JD. Expression of nicotinic acetylcholine receptor subunit genes in non-small-cell lung cancer reveals differences between smokers and nonsmokers. Cancer Res. 2007;67:4638–4647. [PubMed]
  • Laviolette SR, van der Kooy D. The neurobiology of nicotine addiction: bridging the gap from molecules to behaviour. Nat Rev Neurosci. 2004;5:55–65. [PubMed]
  • Le Marchand L, Derby KS, Murphy SE, Hecht SS, Hatsukami D, Carmella SG, Tiirikainen M, Wang H. Smokers with the CHRNA lung cancer-associated variants are exposed to higher levels of nicotine equivalents and a carcinogenic tobacco-specific nitrosamine. Cancer Res. 2008;68:9137–9140. [PMC free article] [PubMed]
  • Le Novère N, Changeux J-P. Molecular evolution of the nicotinic acetylcholine receptor: an example of multigene family in excitable cells. J Mol Evol. 1995;40:155–172. [PubMed]
  • Lena C, Changeux JP. Pathological mutations of nicotinic receptors and nicotine-based therapies for brain disorders. Curr Opin Neurobiol. 1997;7:674–682. [PubMed]
  • Levey MS, Brumwell CL, Dryer SE, Jacob MH. Innervation and target tissue interactions differentially regulate acetylcholine receptor subunit mRNA levels in developing neurons in situ. Neuron. 1995;14:153–162. [PubMed]
  • Levey MS, Jacob MH. Changes in the regulatory effects of cell-cell interactions on neuronal AChR subunit transcript levels after synapse formation. J Neurosci. 1996;16:6878–6885. [PubMed]
  • Levin ED, Rezvani AH. Nicotinic Interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function. Biochem Pharmacol. 2007;74:1182–1191. [PMC free article] [PubMed]
  • Linnoila RI, Zhao B, DeMayo JL, Nelkin BD, Baylin SB, DeMayo FJ, Ball DW. Constitutive achaete-scute homologue-1 promotes airway dysplasia and lung neuroendocrine tumors in transgenic mice. Cancer Res. 2000;60:4005–4009. [PubMed]
  • Liu L, Chang GQ, Jiao YQ, Simon SA. Neuronal nicotinic acetylcholine receptors in rat trigeminal ganglia. Brain Res. 1998;809:238–245. [PubMed]
  • Liu Q, Melnikova IN, Hu M, Gardner PD. Cell type-specific activation of neuronal nicotinic acetylcholine receptor subunit genes by Sox10. J Neurosci. 1999;19:9747–9755. [PubMed]
  • Lukas RJ, Changeux JP, Le Novère N, Albuquerque EX, Balfour DJ, Berg DK, Bertrand D, Chiappinelli VA, Clarke PB, Collins AC, Dani JA, Grady SR, Kellar KJ, Lindstrom JM, Marks MJ, Quik M, Taylor PW, Wonnacott S. International Union of Pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits. Pharmacol Rev. 1999;51:397–401. [PubMed]
  • Macklin KD, Maus AD, Pereira EF, Albuquerque EX, Conti-Fine BM. Human vascular endothelial cells express functional nicotinic acetylcholine receptors. J Pharmacol Exp Ther. 1998;287:435–439. [PubMed]
  • Mai H, May WS, Gao F, Jin Z, Deng X. A functional role for nicotine in Bcl2 phosphorylation and suppression of apoptosis. J Biol Chem. 2003;278:1886–1891. [PubMed]
  • Malin DH, Lake JR, Carter VA, Cunningham JS, Hebert KM, Conrad DL, Wilson OB. The nicotinic antagonist mecamylamine precipitates nicotine abstinence syndrome in the rat. Psychopharmacol. 1994;115:180–184. [PubMed]
  • Malin DH, Lake JR, Upchurch TP, Shenoi M, Rajan N, Schweinle WE. Nicotine abstinence syndrome precipitated by the competitive nicotinic antagonist dihydro-beta-erythroidine. Pharmacol Biochem Behav. 1998;60:609–613. [PubMed]
  • Mandelzys A, Pie B, Deneris ES, Cooper E. The developmental increase in ACh current densities on rat sympathetic neurons correlates with changes in nicotinic ACh receptor alpha-subunit gene expression and occurs independent of innervation. J Neurosci. 1994;14:2357–2364. [PubMed]
  • Maneckjee R, Minna JD. Opioid and nicotine receptors affect growth regulation of human lung cancer cell lines. Proc Natl Acad Sci U S A. 1990;87:3294–3298. [PubMed]
  • Markou A, Paterson NE. The nicotinic antagonist methyllycaconitine has differential effects on nicotine self-administration and nicotine withdrawal in the rat. Nicotine Tob Res. 2001;3:361–373. [PubMed]
  • Marubio LM, Gardier AM, Durier S, David D, Klink R, Arroyo-Jimenez MM, McIntosh JM, Rossi F, Champtiaux N, Zoli M, Changeux JP. Effects of nicotine in the dopaminergic system of mice lacking the alpha4 subunit of neuronal nicotinic acetylcholine receptors. Eur J Neurosci. 2003;17:1329–1337. [PubMed]
  • Maskos U, Molles BE, Pons S, Besson M, Guiard BP, Guilloux JP, Evrard A, Cazala P, Cormier A, Mameli-Engvall M, Dufour N, Cloez-Tayarani I, Bemelmans AP, Mallet J, Gardier AM, David V, Faure P, Granon S, Changeux JP. Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors. Nature. 2005;436:103–107. [PubMed]
  • Maus AD, Pereira EF, Karachunski PI, Horton RM, Navaneetham D, Macklin K, Cortes WS, Albuquerque EX, Conti-Fine BM. Human and rodent bronchial epithelial cells express functional nicotinic acetylcholine receptors. Mol Pharmacol. 1998;54:779–788. [PubMed]
  • McCallum SE, Collins AC, Paylor R, Marks MJ. Deletion of the beta 2 nicotinic acetylcholine receptor subunit alters development of tolerance to nicotine and eliminates receptor upregulation. Psychopharmacology (Berl) 2006;184:314–327. [PubMed]
  • McDonough J, Deneris E. beta43′: An enhancer displaying neural-restricted activity is located in the 3′-untranslated exon of the rat nicotinic acetylcholine receptor beta4 gene. J Neurosci. 1997;17:2273–2283. [PubMed]
  • McDonough J, Francis N, Miller T, Deneris ES. Regulation of transcription in the neuronal nicotinic receptor subunit gene cluster by a neuron-selective enhancer and ETS domain factors. J Biol Chem. 2000;275:28962–28970. [PubMed]
  • McGehee DS, Heath MJ, Gelber S, Devay P, Role LW. Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors. Science. 1995;269:1692–1696. [PubMed]
  • McGehee DS, Role LW. Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. Annu Rev Physiol. 1995;57:521–546. [PubMed]
  • Melnikova IN, Gardner PD. The signal transduction pathway underlying ion channel gene regulation by SP1-C-Jun interactions. J Biol Chem. 2001;276:19040–19045. [PubMed]
  • Melnikova IN, Lin HR, Blanchette AR, Gardner PD. Synergistic transcriptional activation by Sox10 and Sp1 family members. Neuropharm. 2000a;39:2615–2623. [PubMed]
  • Melnikova IN, Yang Y, Gardner PD. Interactions between regulatory proteins that bind to the nicotinic receptor beta4 subunit gene promoter. Eur J Pharmacol. 2000b;393:75–83. [PubMed]
  • Milton NG, Bessis A, Changeux JP, Latchman DS. Differential regulation of neuronal nicotinic acetylcholine receptor subunit gene promoters by Brn-3 POU family transcription factors. Biochem J. 1996;317 ( Pt 2):419–423. [PubMed]
  • Moretti M, Vailati S, Zoli M, Lippi G, Riganti L, Longhi R, Viegi A, Clementi F, Gotti C. Nicotinic acetylcholine receptor subtypes expression during rat retina development and their regulation by visual experience. Molecular Pharmacology. 2004;66:85–96. [PubMed]
  • Morley BJ. The embryonic and post-natal expression of the nicotinic receptor α3-subunit in rat lower brainstem. Mol Brain Res. 1997;48:407–412. [PubMed]
  • Nelson ME, Lindstrom J. Single channel properties of human alpha3 AChRs: impact of beta2, beta4 and alpha5 subunits. J Physiol. 1999;516:657–678. [PubMed]
  • Nguyen VT, Hall LL, Gallacher G, Ndoye A, Jolkovsky DL, Webber RJ, Buchli R, Grando SA. Choline acetyltransferase, acdetylcholinesterase, and nicotinic acetylcholine receptors of human gingival and esophageal epithelia. J Dent Res. 2000;79:939–949. [PubMed]
  • Osada H, Tatematsu Y, Yatabe Y, Horio Y, Takahashi T. ASH1 gene is a specific therapeutic target for lung cancers with neuroendocrine features. Cancer Res. 2005;65:10680–10685. [PubMed]
  • Palma E, Bertrand S, Binzoni T, Bertrand D. Neuronal nicotinic alpha 7 receptor expressed in Xenopus oocytes presents five putative binding sites for methyllycaconitine. J Physiol. 1996;491 ( Pt 1):151–161. [PubMed]
  • Perl O, Ilani T, Strous RD, Lapidus R, Fuchs S. The alpha7 nicotinic acetylcholine receptor in schizophrenia: decreased mRNA levels in peripheral blood lymphocytes. Faseb J. 2003;17:1948–1950. [PubMed]
  • Perry DC, Xiao Y, Nguyen HN, Musachio JL, Dávila-Garcia MI, Kellar KJ. Measuring nicotinic receptors with characteristics of α4β2, α3β2 and α3β4 subtypes in rat tissues by autoradiography. J Neurochem. 2002;82:468–481. [PubMed]
  • Perry EK, Martin-Ruiz CM, Court JA. Nicotinic receptor subtypes in human brain related to aging and dementia. Alcohol. 2001;24:63–68. [PubMed]
  • Picciotto MR, Zoli M, Rimondini R, Lena C, Marubio LM, Pich EM, Fuxe K, Changeux JP. Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature. 1998;391:173–177. [PubMed]
  • Pillai SG, Ge D, Zhu G, Kong X, Shianna KV, Need AC, Feng S, Hersh CP, Bakke P, Gulsvik A, Ruppert A, Lodrup Carlsen KC, Roses A, Anderson W, Rennard SI, Lomas DA, Silverman EK, Goldstein DB. ICGNInvestigators . A Genome-Wide Association Study in Chronic Obstructive Pulmonary Disease (COPD): Identification of Two Major Susceptibility Loci. PLoS Genet. 2009;5:e1000421. [PMC free article] [PubMed]
  • Pons S, Fattore L, Cossu G, Tolu S, Porcu E, McIntosh JM, Changeux JP, Maskos U, Fratta W. Crucial role of alpha4 and alpha6 nicotinic acetylcholine receptor subunits from ventral tegmental area in systemic nicotine self-administration. J Neurosci. 2008;28:12318–12327. [PMC free article] [PubMed]
  • Portugal GS, Gould TJ. Genetic variability in nicotinic acetylcholine receptors and nicotine addiction: converging evidence from human and animal research. Behav Brain Res. 2008;193:1–16. [PMC free article] [PubMed]
  • Proctor RN. Tobacco and the global lung cancer epidemic. Nat Rev Cancer. 2001;1:82–86. [PubMed]
  • Pugh BF, Tjian R. Transcription from a TATA-less promoter requires a multisubunit TFIID complex. Genes Dev. 1991;5:1935–1945. [PubMed]
  • Quik M. Smoking, nicotine and Parkinson’s disease. Trends Neurosci. 2004;27:561–568. [PubMed]
  • Quik M, Bordia T, O’Leary K. Nicotinic receptors as CNS targets for Parkinson’s disease. Biochem Pharmacol. 2007;74:1224–1234. [PMC free article] [PubMed]
  • Quik M, Polonskaya Y, Gillespie A, Jakowec M, Lloyd GK, Langston JW. Localization of nicotinic receptor subunit mRNAs in monkey brain by in situ hybridization. J Comp Neurol. 2000;425:58–69. [PubMed]
  • Ramirez-Latorre J, Yu CR, Qu X, Perin F, Karlin A, Role L. Functional contributions of alpha5 subunit to neuronal acetylcholine receptor channels. Nature. 1996;380:347–351. [PubMed]
  • Richardson CE, Morgan JM, Jasani B, Green JT, Rhodes J, Williams GT, Lindstrom J, Wonnacott S, Thomas GA, Smith V. Megacystis-microcolon-intestinal hypoperistalsis syndrome and the absence of the alpha3 nicotinic acetylcholine receptor subunit. Gastroenterology. 2001;121:350–357. [PubMed]
  • Rogers SW, Gregori NZ, Carlson N, Gahring LC, Noble M. Neuronal nicotinic acetylcholine receptor expression by O2A/oligodendrocyte progenitor cells. Glia. 2001;33:306–313. [PubMed]
  • Romanelli MN, Gratteri P, Guandalini L, Martini E, Bonaccini C, Gualtieri F. Central nicotinic receptors: structure, function, ligands, and therapeutic potential. ChemMedChem. 2007;2:746–767. [PubMed]
  • Rust G, Burgunder JM, Lauterburg TE, Cachelin AB. Expression of neuronal nicotinic acetylcholine receptor subunit genes in the rat autonomic nervous system. Eur J Neurosci. 1994;6:478–485. [PubMed]
  • Saccone NL, Saccone SF, Hinrichs AL, Stitzel JA, Duan W, Pergadia ML, Agrawal A, Breslau N, Grucza RA, Hatsukami D, Johnson EO, Madden PA, Swan GE, Wang JC, Groate AM, Rice JP, Bierut LJ. Multiple distinct risk loci for nicotine dependence identified by dense coverage of the complete family of nicotinic receptor subunit (CHRN) genes. Am J Med Genet B Neuropsychiatr Genet. 2009a;150B:453–466. [PMC free article] [PubMed]
  • Saccone NL, Wang JC, Breslau N, Johnson EO, Hatsukami D, Saccone SF, Grucza RA, Sun L, Duan W, Budde J, Culverhouse RC, Fox L, Hinrichs AL, Steinbach JH, Wu M, Rice JP, Goate AM, Bierut LJ. The CHRNA5-CHRNA3-CHRNB4 nicotinic receptor subunit gene cluster afects risk for nicotine dependence in African-Americans and in European-Americans. Cancer Res. 2009b;69:6848–6856. [PMC free article] [PubMed]
  • Saccone SF, Hinrichs AL, Saccone NL, Chase GA, Konvicka K, Madden PA, Breslau N, Johnson EO, Hatsukami D, Pomerleau O, Swan GE, Goate AM, Rutter J, Bertelsen S, Fox L, Fugman D, Martin NG, Montgomery GW, Wang JC, Ballinger DG, Rice JP, Bierut LJ. Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. Hum Mol Genet. 2007;16:36–49. [PMC free article] [PubMed]
  • Sack R, Gochberg-Sarver A, Rozovsky U, Kedmi M, Rosner S, Orr-Urtreger A. Lower core body temperature and attenuated nicotine-induced hypothermic response in mice lacking the beta4 neuronal nicotinic acetylcholine receptor subunit. Brain Res Bull. 2005;66:30–36. [PubMed]
  • Salas R, Cook KD, Bassetto L, De Biasi M. The α3 and β4 nicotinic receptor subunits are necessary for nicotine-induced seizures and hypolocomotion in mice. Neuropharmacology. 2004a;47:401–407. [PubMed]
  • Salas R, Orr-Urtreger A, Broide RS, Beaudet A, Paylor R, De Biasi M. The nicotinic acetylcholine receptor subunit alpha 5 mediates short-term effects of nicotine in vivo. Mol Pharmacol. 2003a;63:1059–1066. [PubMed]
  • Salas R, Pieri F, De Biasi M. Decreased signs of nicotine withdrawal in mice null for the beta4 nicotinic acetylcholine receptor subunit. J Neurosci. 2004b;24:10035–10039. [PubMed]
  • Salas R, Pieri F, Fung B, Dani JA, De Biasi M. Altered anxiety-related responses in mutant mice lacking the beta4 subunit of the nicotinic receptor. J Neurosci. 2003b;23:6255–6263. [PubMed]
  • Salas R, Sturm R, Boulter J, De Biasi M. Nicotinic receptors in the habenulo-interpeduncular system are necessary for nicotine withdrawal in mice. J Neurosci. 2009;29:3014–3018. [PubMed]
  • Salminen O, Drapeau JA, McIntosh JM, Collins AC, Marks MJ, Grady SR. Pharmacology of alpha-conotoxin MII-sensitive subtypes of nicotinic acetylcholine receptors isolated by breeding of null mutant mice. Mol Pharmacol. 2007;71:1563–1571. [PubMed]
  • Sartelet H, Maouche K, Totobenazara JL, Petit J, Burlet H, Monteau M, Tournier JM, Birembaut P. Expression of nicotinic receptors in normal and tumoral pulmonary neuroendocrine cells (PNEC) Pathology - Research and Practice. 2008;204:891–898. [PubMed]
  • Sasaki H, Hikosaka Y, Okuda K, Kawano O, Yukiue H, Yano M, Fujii Y. CHRNA5 gene D398N polymorphism in Japanese lung adenocarcinoma. J Surg Res. 2009 Epub ahead of print. [PubMed]
  • Schlaepfer IR, Hoft NR, Collins AC, Corley RP, Hewitt JK, Hopfer CJ, Lessern JM, McQueen MB, Hyun Rhee S, Ehringer MA. The CHRNA5/A3/B4 gene cluster variability as an important determinant of early alcohol and tobacco initiation in young adults. Biol Psych. 2008;63:1039–1046. [PMC free article] [PubMed]
  • Schuller HM. Cell type specific receptor-mediated modulation of growth kinetics in human lung cancer cell lines by nicotine and tobacco-related nitrosamines. Biochem Pharmacol. 1989;38:3439–3442. [PubMed]
  • Schuller HM. Neurotransmission and cancer: implications for prevention and therapy. Anti-Cancer Drugs. 2008;19:655–671. [PubMed]
  • Schuller HM. Is cancer triggered by altered signalling of nicotinic acetylcholine receptors? Nat Rev Cancer. 2009;9:195–205. [PubMed]
  • Schuller HM, McGavin MD, Orloff M, Riechert A, Porter B. Simultaneous exposure to nicotine and hyperoxia causes tumors in hamsters. Lab Invest. 1995;73:448–456. [PubMed]
  • Schuller HM, Orloff M. Tobacco-specific carcinogenic nitrosamines. Ligands for nicotinic acetylcholine receptors in human lung cancer cells. Biochem Pharmacol. 1998;55:1377–1384. [PubMed]
  • Schwartz AG, Cote ML, Wenzlaff AS, Land S, Amos CI. Racial differences in the association between SNPs on 15q25.1, smoking behavior, and risk of non-small cell lung cancer. J Thorac Oncol. 2009;4:1195–1201. [PMC free article] [PubMed]
  • Scofield MD, Bruschweiler-Li L, Mou Z, Gardner PD. Transcription factor assembly on the nicotinic receptor β4 subunit gene promoter. Neuroreport. 2008;19:687–690. [PubMed]
  • Senba E, Simmons DM, Wada E, Wada K, Swanson LW. RNA levels of neuronal nicotinic acetylcholine receptor subunits are differentially regulated in axotomized facial motoneurons: an in situ hybridization study. Mol Brain Res. 1990;8:349–353. [PubMed]
  • Sharma G, Vijayaraghavan S. Nicotinic receptor signaling in nonexcitable cells. J Neurobiol. 2002;53:524–534. [PubMed]
  • Sherva R, Wilhelmsen K, Pomerleau CS, Chasse SA, Rice JP, Snedecor SM, Bierut LJ, Neuman RJ, Pomerleau OF. Association of a single nucleotide polymorphism in neuronal acetylcholine receptor subunit alpha 5 (CHRNA5) with smoking status and with ‘pleasurable buzz’ during early experimentation with smoking. Addiction. 2008;103:1544–1552. [PMC free article] [PubMed]
  • Shields PG. Molecular epidemiology of smoking and lung cancer. Oncogene. 2002;21:6870–6876. [PubMed]
  • Shimakura J, Terada T, Shimada Y, Katsura T, Inui K. The transcription factor Cdx2 regulates the intestine-specific expression of human peptide transporter 1 through functional interaction with Sp1. Biochem Pharmacol. 2006;71:1581–1588. [PubMed]
  • Silver AA, Shytle RD, Philipp MK, Wilkinson BJ, McConville B, Sanberg PR. Transdermal nicotine and haloperidol in Tourette’s disorder: a double-blind placebo-controlled study. J Clin Psychiatry. 2001;62:707–714. [PubMed]
  • Song P, Sekhon HS, Fu XW, Maier M, Jia Y, Duan J, Proskosil BJ, Gravett C, Lindstrom J, Mark GP, Saha S, Spindel ER. Activated cholinergic signaling provides a target in squamous cell lung carcinoma. Cancer Res. 2008;68:4693–4700. [PMC free article] [PubMed]
  • Song P, Sekhon HS, Jia Y, Keller JA, Blusztajn JK, Mark GP, Spindel ER. Acetycholine is synthesized by and acts as an autocrine growth factor for small cell lung carcinoma. Cancer Res. 2003;63:214–221. [PubMed]
  • Spindel ER. Neuronal nicotinic acetylcholine receptors: not just in brain. Am J Physiol Lung Cell Mol Physiol. 2003;285:L1201–L1202. [PubMed]
  • Spitz MR, Amos CI, Dong Q, Lin J, Wu X. The CHRNA5-A3 region on chromosome 15q24–25.1 is a risk factor both for nicotine dependence and for lung cancer. J Natl Cancer Inst. 2008;100:1552–1556. [PMC free article] [PubMed]
  • Steen KH, Reeh PW. Actions of cholinergic agonists and antagonists on sensory nerve endings in rat skin, in vitro. J Neurophysiol. 1993;70:397–405. [PubMed]
  • Steinlein OK, Mulley JC, Propping P, Wallace RH, Phillips HA, Sutherland GR, Scheffer IE, Berkovic SF. A missense mutation in the neuronal nicotinic acetylcholine receptor alpha 4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy. Nat Genet. 1995;11:201–203. [PubMed]
  • Stevens VL, Bierut LJ, Talbot JT, Wang JC, Sun J, Hinrichs AL, Thun MJ, Goate A, Calle EE. Nicotinic receptor gene variants influence susceptibility to heavy smoking. Cancer Epidemiol Biomarkers Prev. 2008;17:3517–3525. [PMC free article] [PubMed]
  • Sucher NJ, Cheng TP, Lipton SA. Neural nicotinic acetylcholine responses in sensory neurons from postnatal rat. Brain Res. 1990;533:248–254. [PubMed]
  • Suzuki T, Ise Y, Maeda J, Misawa M. Mecamylamine-precipitated nicotine-withdrawal aversion in Lewis and Fischer 344 inbred rat strains. Eur J Pharmacol. 1999;369:159–162. [PubMed]
  • Suzuki T, Ise Y, Tsuda M, Maeda J, Misawa M. Mecamylamine-precipitated nicotine-withdrawal aversion in rats. Eur J Pharmacol. 1996;314:281–284. [PubMed]
  • Taly A, Corringer P-J, Guedin D, Lestage P, Changeux J-P. Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system. Nat Rev Drug Discov. 2009;8:733–750. [PubMed]
  • Tapper AR, McKinney SL, Marks MJ, Lester HA. Nicotine responses in hypersensitive and knockout alpha 4 mice account for tolerance to both hypothermia and locomotor suppression in wild-type mice. Physiol Genomics. 2007;31:422–428. [PubMed]
  • Tapper AR, McKinney SL, Nashmi R, Schwarz J, Deshpande P, Labarca C, Whiteaker P, Marks MJ, Collins AC, Lester HA. Nicotine activation of alpha4* receptors: sufficient for reward, tolerance, and sensitization. Science. 2004;306:1029–1032. [PubMed]
  • Teaktong T, Graham A, Court J, Perry R, Jaros E, Johnson M, Hall R, Perry E. Alzheimer’s disease is associated with a selective increase in alpha7 nicotinic acetylcholine receptor immunoreactivity in astrocytes. Glia. 2003;41:207–211. [PubMed]
  • Terzano S, Court JA, Fornasari D, Griffiths M, Spurden DP, Lloyd S, Perry RH, Perry EK, Clementi F. Expression of the alpha3 nicotinic receptor subunit mRNA in aging and Alzheimer’s disease. Brain Res Mol Brain Res. 1998;63:72–78. [PubMed]
  • Terzano S, Flora A, Clementi F, Fornasari D. The minimal promoter of the human alpha 3 nicotinic receptor subunit gene. Molecular and functional characterization. J Biol Chem. 2000;275:41495–41503. [PubMed]
  • Thorgeirsson TE, Geller F, Sulem P, Rafnar T, Wiste A, Magnusson KP, Manolescu A, Thorleifsson G, Stefansson H, Ingason A, Stacey SN, Bergthorsson JT, Thorlacius S, Gudmundsson J, Jonsson T, Jakobsdottir M, Saemundsdottir J, Olafsdottir O, Gudmundsson LJ, Bjornsdottir G, Kristjansson K, Skuladottir H, Isaksson HJ, Gudbjartsson T, Jones GT, Mueller T, Gottsäter A, Flex A, Aben KKH, de Vegt F, Mulders PFA, Isla D, Vidal MJ, Asin L, Saez B, Murillo L, Blondal T, Kolbeinsson H, Stefansson JG, Hansdottir I, Runarsdottir V, Pola R, Lindblad B, van Rij AM, Dieplinger B, Haltmayer M, Mayordomo JI, Kiemeney LA, Matthiasson SE, Oskarsson H, Tyrfingsson T, Gudbjartsson DF, Gulcher JR, Jonsson S, Thorsteinsdottir U, Kong A, Stefansson K. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature. 2008;452:638–642. [PubMed]
  • Turner JR, Kellar KJ. Nicotinic cholinergic receptors in the rat cerebellum: multiple heteromeric subtypes. J Neurosci. 2005;25:9258–9265. [PubMed]
  • Valor LM, Campos-Caro A, Carrasco-Serrano C, Ortiz JA, Ballesta JJ, Criado M. Transcription factors NF-Y and Sp1 are important determinants of the promoter activity of the bovine and human neuronal nicotinic receptor beta 4 subunit genes. J Biol Chem. 2002;277:8866–8876. [PubMed]
  • Vernallis AB, Conroy WG, Berg DK. Neurons assemble acetylcholine receptors with as many as three kinds of subunits while maintaining subunit segregation among receptor subtypes. Neuron. 1993;10:451–464. [PubMed]
  • Vernino S, Amador M, Luetje CW, Patrick J, Dani JA. Calcium modulation and high calcium permeability of neuronal nicotinic acetylcholine receptors. Neuron. 1992;8:127–134. [PubMed]
  • Vink JM, Smit AB, de Geus EJC, Sullivan P, Willemsen G, Hottenga J-J, Smit JH, Hoogendijk WJ, Zitman FG, Peltonen L, Kaprio J, Pedersen NL, Magnusson PK, Spector TD, Kyvik KO, Morley KI, Heath AC, Martin NGRGW, Slagboom PE, Tiemeier H, Hofman A, Uitterlinden AG, Aulchenko YS, Amin N, van Duijn C, Penninx BW, Boomsma DI. Genome-wide association study of smoking initiation and current smoking. Am J Hum Genet. 2009;84:367–379. [PubMed]
  • Wada E, McKinnon D, Heinemann S, Patrick J, Swanson LW. The distribution of mRNA encoded by a new member of the neuronal nicotinic acetylcholine receptor gene family (alpha 5) in the rat central nervous system. Brain Res. 1990;526:45–53. [PubMed]
  • Wada E, Wada K, Boulter J, Deneris E, Heinemann S, Patrick J, Swanson LW. Distribution of alpha 2, alpha 3, alpha 4, and beta 2 neuronal nicotinic receptor subunit mRNAs in the central nervous system: a hybridization histochemical study in the rat. J Comp Neurol. 1989;284:314–335. [PubMed]
  • Wada K, Ballivet M, Boulter J, Connolly J, Wada E, Deneris ES, Swanson LW, Heinemann S, Patrick J. Functional expression of a new pharmacological subtype of brain nicotinic acetylcholine receptor. Science. 1988;240:330–334. [PubMed]
  • Wang F, Gerzanich V, Wells GB, Anand R, Peng X, Keyser K, Lindstrom J. Assembly of human neuronal nicotinic receptor alpha5 subunits with alpha3, beta2, and beta4 subunits. J Biol Chem. 1996;271:17656–17665. [PubMed]
  • Wang JC, Cruchaga C, Saccone NL, Bertelsen S, Liu P, Budde JP, Duan W, Fox L, Grucza RA, Kern J, Mayo K, Reyes O, Rice J, Saccone SF, Spiegel N, Steinbach JH, Stitzel JA, Anderson MW, You M, Stevens VL, Bierut LJ, Goate AM. collaborators C and collaborators G. Risk for nicotine dependence and lung cancer is conferred by mRNA expression levels and amino acid change in CHRNA5. Hum Mol Genet. 2009a;18:3125–3135. [PMC free article] [PubMed]
  • Wang JC, Grucza R, Cruchaga C, Hinrichs AL, Bertelsen S, Budde JP, Fox L, Goldstein E, Reyes O, Saccone N, Saccone S, Xuei X, Bucholz K, Kuperman S, Nurnberger JJ, Rice JP, Schuckit M, Tischfield J, Hesselbroc V, Porjesz B, Edenberg HJ, Bierut LJ, Goate AM. Genetic variation in the CHRNA5 gene affects mRNA levels and is associated with risk for alcohol dependence. Mol Psych. 2009b;14:501–510. [PubMed]
  • Wang N, Orr-Urtreger A, Chapman J, Rabinowitz R, Korczyn AD. Deficiency of nicotinic acetylcholine receptor β4 subunit causes autonomic cardiac and intestinal dysfunction. Mol Pharmacol. 2003;63:574–580. [PubMed]
  • Wang N, Orr-Urtreger A, Chapman J, Rabinowitz R, Nachman R, Korczyn AD. Autonomic function in mice lacking alpha5 neuronal nicotinic acetylcholine receptor subunit. J Physiol. 2002a;542:347–354. [PubMed]
  • Wang N, Orr-Urtreger A, Korczyn AD. The role of neuronal nicotinic acetylcholine receptor subunits in autonomic ganglia: lessons from knockout mice. Prog Neurobiol. 2002b;68:341–360. [PubMed]
  • Wang Y, Pereira EF, Maus AD, Ostlie NS, Navaneetham D, Lei S, Albuquerque EX, Conti-Fine BM. Human bronchial epithelial and endothelial cells express alpha7 nicotinic acetylcholine receptors. Mol Pharmacol. 2001;60:1201–1209. [PubMed]
  • Ward JM, Cockcroft VB, Lunt GG, Smillie FS, Wonnacott S. Methyllycaconitine: a selective probe for neuronal alpha-bungarotoxin binding sites. FEBS Lett. 1990;270:45–48. [PubMed]
  • Watkins SS, Stinus L, Koob GF, Markou A. Reward and somatic changes during precipitated nicotine withdrawal in rats: centrally and peripherally mediated effects. J Pharmacol Exp Ther. 2000;292:1053–1064. [PubMed]
  • Weiss RB, Baker TB, Cannon DS, von Niederhausern A, Dunn DM, Matsunami N, Singh NA, Baird L, Coon H, McMahon WM, Piper ME, Fiore MC, Scholend MB, Connett JE, Kanner RE, Gahring LC, Rogers SW, Hoidal JR, Leppert MF. A candidate gene approach identifies the CHRNA5-A3-B4 region as a risk factor for age-dependent nicotine addiction. PLOS Genetics. 2008;4:e1000125. [PMC free article] [PubMed]
  • Wessler I, Kirkpatrick CJ. Acetylcholine beyond neurons: the non-neuronal cholinergic system in humans. Brit J Pharmacol. 2008;154:1558–1571. [PubMed]
  • West KA, Brognard J, Clark AS, Linnoila IR, Yang X, Swain SM, Harris C, Belinsky S, Dennis PA. Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J Clin Invest. 2003;111:81–90. [PMC free article] [PubMed]
  • Whitehouse PJ, Martino AM, Marcus KA, Zweig RM, Singer HS, Price DL, Kellar KJ. Reductions in acetylcholine and nicotine binding in several degenerative diseases. Arch Neurol. 1988;45:722–724. [PubMed]
  • Winzer-Serhan UH, Leslie FM. Codistribution of nicotinic acetylcholine receptor subunit alpha3 and beta4 mRNAs during rat brain development. J Comp Neurol. 1997;386:540–554. [PubMed]
  • Wu C, Hu Z, Yu D, Huang L, Jin G, Liang J, Guo H, Tan W, Zhang M, Qian J, Lu D, Wu T, Lin D, Shen H. Genetic variants on chromosome 15q25 associated with lung cancer risk in Chinese populations. Cancer Res. 2009;69:5065–5072. [PubMed]
  • Xin M, Deng X. Nicotine inactivation of the proapoptotic function of Bax through phosphorylation. J Biol Chem. 2005;280:10781–10789. [PubMed]
  • Xu W, Gelber S, Orr-Urtreger A, Armstrong D, Lewis RA, Ou C-N, Patrick J, Role L, De Biasi M, Beaudet AL. Megacystis, mydriasis, and ion channel defect in mice lacking the α3 neuronal nicotinic acetylcholine receptor. Proc Natl Acad Sci U S A. 1999a;96:5746–5751. [PubMed]
  • Xu W, Orr-Urtreger A, Nigro F, Gelber S, Sutcliffe CB, Armstrong D, Patrick JW, Role LW, Beaudet AL, De Biasi M. Multiorgan autonomic dysfunction in mice lacking the beta2 and the beta4 subunits of neuronal nicotinic acetylcholine receptors. J Neurosci. 1999b;19:9298–9305. [PubMed]
  • Xu X, Scott MM, Deneris ES. Shared long-range regulatory elements coordinate expression of a gene cluster encoding nicotinic receptor heteromeric subtypes. Mol Cell Biol. 2006;26:5636–5649. [PMC free article] [PubMed]
  • Yang X, Fyodorov D, Deneris ES. Transcriptional analysis of acetylcholine receptor alpha 3 gene promoter motifs that bind Sp1 and AP2. J Biol Chem. 1995;270:8514–8520. [PubMed]
  • Yang X, McDonough J, Fyodorov D, Morris M, Wang F, Deneris ES. Characterization of an acetylcholine receptor alpha 3 gene promoter and its activation by the POU domain factor SCIP/Tst-1. J Biol Chem. 1994;269:10252–10264. [PubMed]
  • Yang X, Yang F, Fyodorov D, Wang F, McDonough J, Herrup K, Deneris E. Elements between the protein-coding regions of the adjacent beta 4 and alpha 3 acetylcholine receptor genes direct neuron-specific expression in the central nervous system. J Neurobiol. 1997;32:311–324. [PubMed]
  • Zanardi A, Leo G, Biagini G, Zoli M. Nicotine and neurodegeneration in ageing. Toxicol Lett. 2002;127:207–215. [PubMed]
  • Zhou Y, Deneris E, Zigmond RE. Differential regulation of levels of nicotinic receptor subunit transcripts in adult sympathetic neurons after axotomy. J Neurobiol. 1998;34:164–178. [PubMed]
  • Zia S, Ndoye A, Lee TX, Webber RJ, Grando SA. Receptor-mediated inhibition of keratinocyte migration by nicotine involves modulations of calcium influx and intracellular concentration. J Pharmacol Exp Ther. 2000;293:973–981. [PubMed]
  • Zoli M, Le Novere N, Hill JA, Jr, Changeux JP. Developmental regulation of nicotinic ACh receptor subunit mRNAs in the rat central and peripheral nervous systems. J Neurosci. 1995;15:1912–1939. [PubMed]
  • Zoli M, Moretti M, Zanardi A, McIntosh JM, Clementi F, Gotti C. Identification of the nicotinic receptor subtypes expressed on dopaminergic terminals in the rat striatum. J Neurosci. 2002;22:8785–8789. [PubMed]